209 results on '"LaRosa J"'
Search Results
2. The radioactive source calibration system of the PROSPECT reactor antineutrino detector
- Author
-
Ashenfelter, J., Balantekin, A.B., Band, H.R., Bass, C.D., Bergeron, D.E., Berish, D., Bowden, N.S., Brodsky, J.P., Bryan, C.D., Cherwinka, J.J., Classen, T., Conant, A.J., Dean, D., Deichert, G., Diwan, M.V., Dolinski, M.J., Erickson, A., Febbraro, M., Foust, B.T., Gaison, J.K., Galindo-Uribarri, A., Gilbert, C.E., Hackett, B.T., Hans, S., Hansell, A.B., Heeger, K.M., Insler, J., Jaffe, D.E., Jones, D.C., Kyzylova, O., Lane, C.E., Langford, T.J., LaRosa, J., Littlejohn, B.R., Lu, X., Caicedo, D.A. Martinez, Matta, J.T., McKeown, R.D., Mendenhall, M.P., Mueller, P.E., Mumm, H.P., Napolitano, J., Neilson, R., Nikkel, J.A., Norcini, D., Nour, S., Pushin, D.A., Qian, X., Romero-Romero, E., Rosero, R., Sarenac, D., Surukuchi, P.T., Telles, A.B., Tyra, M.A., Varner, R.L., Viren, B., White, C., Wilhelmi, J., Wise, T., Yeh, M., Yen, Y.-R., Zhang, A., Zhang, C., and Zhang, X.
- Published
- 2019
- Full Text
- View/download PDF
3. Final Measurement of the U235 Antineutrino Energy Spectrum with the PROSPECT-I Detector at HFIR
- Author
-
Adriamirado, M., Balantekin, A. B., Bass, C. D., Bergeron, D. E., Bernard, E. P., Bowden, N. S., Bryan, C. D., Carr, R., Classen, T., Conant, A. J., Deichert, G., Delgado, A., Diwan, M. V., Dolinski, M. J., Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribari, A., Gilbert, C. E., Gokhale, S., Grant, C., Hans, S., Hansell, A. B., Heeger, K. M., Heffron, B., Jaffe, D. E., Jayakumar, S., Ji, X., Jones, D. C., Koblanski, J., Kunkle, P., Kyzylova, O., LaBelle, D., Lane, C. E., Langford, T. J., LaRosa, J., Littlejohn, B. R., Lu, X., Maricic, J., Mendenhall, M. P., Meyer, A. M., Milincic, R., Mueller, P. E., Mumm, H. P., Napolitano, J., Neilson, R., Nikkel, J. A., Nour, S., Gallo, J. L. Palomino, Pushin, D. A., Qian, X., Roca, C., Rosero, R., Searles, M., Surukuchi, P. T., Sutanto, F., Tyra, M. A., Venegas-Vargas, D., Weatherly, P. B., Wilhelmi, J., Woolverton, A., Yeh, M., Zhang, C., and Zhang, X.
- Subjects
High Energy Physics - Experiment (hep-ex) ,FOS: Physical sciences ,Nuclear Experiment (nucl-ex) ,Nuclear Experiment ,High Energy Physics - Experiment - Abstract
This Letter reports one of the most precise measurements to date of the antineutrino spectrum from a purely U235-fueled reactor, made with the final dataset from the PROSPECT-I detector at the High Flux Isotope Reactor. By extracting information from previously unused detector segments, this analysis effectively doubles the statistics of the previous PROSPECT measurement. The reconstructed energy spectrum is unfolded into antineutrino energy and compared with both the Huber-Mueller model and a spectrum from a commercial reactor burning multiple fuel isotopes. A local excess over the model is observed in the 5MeV to 7MeV energy region. Comparison of the PROSPECT results with those from commercial reactors provides new constraints on the origin of this excess, disfavoring at 2.2 and 3.2 standard deviations the hypotheses that antineutrinos from U235 are solely responsible and non-contributors to the excess observed at commercial reactors respectively., The paper has been updated with an improved parametrization of the observed antineutrino spectrum excess and extended discussion on its potential isotopic origin
- Published
- 2022
4. High Energy Physics Opportunities Using Reactor Antineutrinos
- Author
-
Awe, C., Barbeau, P. S., Haghighat, A., Huber, P., Li, S. C., Link, J. M., Mascolino, V., Subedi, T., Walkup, K., Aguilar-Arevalo, A., Bertou, X., Bonifazi, C., Cancelo, G., Cervantes-Vergara, B. A., Chavez, C., D Olivo, J. C., Egea, J. M., Dos Anjos, J. C., Estrada, J., Neto, A. R. F., Fernandez-Moroni, G., Foguel, A., Ford, R., Gasanego, J., Gollo, V., Izraelevitch, F., Kilminster, B., Lima, Jr H. P., Makler, M., Mendes, L. H., Molina, J., Mota, P., Nasteva, I., Paolini, E., Romero, C., Sarkis, Y., Haro, M. S., Soto, A., Stalder, D., Tiffenberg, J., Torres, C., Lindner, M., An, F. P., Balantekin, A. B., Band, H. R., Bishai, M., Blyth, S., Cao, G. F., Cao, J., Chang, J. F., Chang, Y., Chen, H. S., Chen, S. M., Chen, Y., Chen, Y. X., Cheng, J., Cheng, Z. K., Cherwinka, J. J., Chu, M. C., Cummings, J. P., Dalager, O., Deng, F. S., Ding, Y. Y., Diwan, M. V., Dohnal, T., Dove, J., Dvořák, M., Dwyer, D. A., Gallo, J. P., Gonchar, M., Gong, G. H., Gong, H., Gu, W. Q., Guo, J. Y., Guo, L., Guo, X. H., Guo, Y. H., Guo, Z., Hackenburg, R. W., Hans, S., He, M., Heeger, K. M., Heng, Y. K., Higuera, A., Hor, Y. K., Hsiung, Y. B., Hu, B. Z., Hu, J. R., Hu, T., Hu, Z. J., Huang, H. X., Huang, X. T., Jaffe, D. E., Jen, K. L., Ji, X. L., Ji, X. P., Johnson, R. A., Jones, D., Kang, L., Kettell, S. H., Kohn, S., Kramer, M., Langford, T. J., Lee, J., Lee, J. H. C., Lei, R. T., Leitner, R., Leung, J. K. C., Li, F., Li, H. L., Li, J. J., Li, Q. J., Li, S., Li, W. D., Li, X. N., Li, X. Q., Li, Y. F., Li, Z. B., Liang, H., Lin, C. J., Lin, G. L., Lin, S., Ling, J. J., Littenberg, L., Littlejohn, B. R., Liu, J. C., Liu, J. L., Lu, C., Lu, H. Q., Lu, J. S., Luk, K. B., Ma, X. B., Ma, X. Y., Ma, Y. Q., Mandujano, R. C., Marshall, C., Martinez Caicedo, D. A., Mcdonald, K. T., Mckeown, R. D., Meng, Y., Napolitano, J., Naumov, D., Naumova, E., Ochoa-Ricoux, J. P., Olshevskiy, A., Pan, H. -R, Park, J., Patton, S., Peng, J. C., Pun, C. S. J., Qi, F. Z., Qi, M., Qian, X., Raper, N., Ren, J., Reveco, C. Morales, Rosero, R., Roskovec, B., Ruan, X. C., Steiner, H., Sun, J. L., Tmej, T., Treskov, K., Tse, W. -H, Tull, C. E., Viren, B., Vorobel, V., Wang, C. H., Wang, J., Wang, M., Wang, N. Y., Wang, R. G., Wang, W., Wang, X., Wang, Y., Wang, Y. F., Wang, Z., Wang, Z. M., Wei, H. Y., Wei, L. H., Wen, L. J., Whisnant, K., White, C. G., Wong, H. L. H., Worcester, E., Wu, D. R., Wu, F. L., Wu, Q., Wenjie Wu, Xia, D. M., Xie, Z. Q., Xing, Z. Z., Xu, J. L., Xu, T., Xue, T., Yang, C. G., Yang, L., Yang, Y. Z., Yao, H. F., Ye, M., Yeh, M., Young, B. L., Yu, H. Z., Yu, Z. Y., Yue, B. B., Zeng, S., Zeng, Y., Zhan, L., Zhang, C., Zhang, F. Y., Zhang, H. H., Zhang, J. W., Zhang, Q. M., Zhang, X. T., Zhang, Y. M., Zhang, Y. X., Zhang, Y. Y., Zhang, Z. J., Zhang, Z. P., Zhang, Z. Y., Zhao, J., Zhou, L., Zhuang, H. L., Zou, J. H., Abusleme, A., Adam, T., Ahmad, S., Ahmed, R., Aiello, S., An, G. P., An, Q., Andronico, G., Anfimov, N., Antonelli, V., Antoshkina, T., Asavapibhop, B., André, J. P. A. M., Auguste, D., Babic, A., Baldini, W., Barresi, A., Baussan, E., Bellato, M., Bergnoli, A., Bernieri, E., Birkenfeld, T., Blin, S., Blum, D., Bolshakova, A., Bongrand, M., Bordereau, C., Breton, D., Brigatti, A., Brugnera, R., Bruno, R., Budano, A., Buesken, M., Buscemi, M., Busto, Jose, Butorov, I., Cabrera, A., Cai, H., Cai, X., Cai, Y. K., Cai, Z. Y., Cammi, A., Campeny, A., Cao, C. Y., Caruso, R., Cerna, C., Chakaberia, I., Chen, P. P., Chen, P. A., Chen, S., Chen, X., Chen, Y. W., Chen, Z., Cheng, Y., Chiesa, D., Chimenti, P., Chukanov, A., Chuvashova, A., Claverie, G., Clementi, C., Clerbaux, B., Di Lorenzo, S., Corti, D., Costa, S., Corso, F. D., La Taille, C., Deng, J., Deng, Z., Deng, Z. Y., Depnering, W., Diaz, M., Ding, X. F., Dirgantara, B., Dmitrievsky, S., Donchenko, G., Dong, J. M., Dornic, D., Doroshkevich, E., Dracos, M., Druillole, F., Du, S. X., Dusini, S., Dvorak, M., Enqvist, T., Enzmann, H., Fabbri, A., Fajt, L., Fan, D. H., Fan, L., Fang, C., Fang, J., Fang, W. X., Fargetta, M., Fatkina, A., Fedoseev, D., Fekete, V., Feng, L. C., Feng, Q. C., Formozov, A., Fournier, A., Gan, H. N., Gao, F., Garfagnini, A., Göttel, A., Genster, C., Giammarchi, M., Giaz, A., Giudice, N., Gong, G., Gorchakov, O., Gornushkin, Y., Grassi, M., Grewing, C., Gromov, V., Gu, M., Gu, X., Gu, Y., Guan, M. Y., Guardone, N., Gul, M., Guo, C., Guo, W. L., Hackspacher, P., Hagner, C., Han, R., Han, Y., Hassan, M., He, W., Heinz, T., Hellmuth, P., Herrera, R., Hong, D. J., Hou, S. J., Hsiung, Y., Hu, H., Hu, J., Hu, S. Y., Huang, C. H., Huang, G. H., Huang, Q. H., Huang, W. H., Huang, X., Huang, Y. B., Hui, J. Q., Huo, L., Huo, W., Huss, C., Hussain, S., Insolia, A., Ioannisian, A., Isocrate, R., Ji, X. Z., Jia, H. H., Jia, J. J., Jian, S. Y., Jiang, D., Jiang, X. S., Jin, R. Y., Jing, X. P., Jollet, C., Joutsenvaara, J., Jungthawan, S., Kalousis, L., Kampmann, P., Karagounis, M., Kazarian, N., Khan, A., Khan, W., Khosonthongkee, K., Kinz, P., Korablev, D., Kouzakov, K., Krasnoperov, A., Krumshteyn, Z., Kruth, A., Kutovskiy, N., Kuusiniemi, P., Lachenmaier, T., Landini, C., Leblanc, S., Lebrin, V., Lefevre, F., Lei, R., Leung, J., Li, C., Li, D., Li, H., Li, J., Li, K. J., Li, M. Z., Li, M., Li, N., Li, R. H., Li, S. F., Li, S. J., Li, T., Li, W. G., Li, X. M., Li, X. L., Li, Y., Li, Z., Li, Z. Y., Liang, J. J., Liebau, D., Limphirat, A., Limpijumnong, S., Lin, S. X., Lin, T., Lippi, I., Liu, F., Liu, H. D., Liu, H. B., Liu, H. J., Liu, H. T., Liu, H., Liu, M., Liu, Q., Liu, R. X., Liu, S. Y., Liu, S. B., Liu, S. L., Liu, X. W., Liu, X., Liu, Y., Lokhov, A., Lombardi, P., Lombardo, C., Loo, K., Lu, J. B., Lu, J. G., Lu, S. X., Lu, X. X., Lubsandorzhiev, B., Lubsandorzhiev, S., Ludhova, L., Luo, F. J., Luo, G., Luo, P. W., Luo, S., Luo, W. M., Lyashuk, V., Ma, Q. M., Ma, S., Maalmi, J., Malyshkin, Y., Mantovani, F., Manzali, F., Mao, X., Mao, Y. J., Mari, S. M., Marini, F., Marium, S., Martellini, C., Martin-Chassard, G., Martini, A., Mayilyan, D., Müller, A., Mednieks, I., Meregaglia, A., Meroni, E., Meyhöfer, D., Mezzetto, M., Miller, J., Miramonti, L., Monforte, S., Montini, P., Montuschi, M., Morozov, N., Muhammad, A., Muralidharan, P., Nastasi, M., Naumov, D. V., Nemchenok, I., Ning, F. P., Ning, Z., Nunokawa, H., Oberauer, L., Orestano, D., Ortica, F., Pan, H. R., Paoloni, A., Parkalian, N., Parmeggiano, S., Payupol, T., Pei, Y., Pelliccia, N., Peng, A., Peng, H., Perrot, F., Petitjean, P. A., Petrucci, F., Piñeres Rico, L. F., Pilarczyk, O., Popov, A., Poussot, P., Pratumwan, W., Previtali, E., Qi, F., Qian, S., Qian, X. H., Qiao, H., Qin, Z. H., Qiu, S. K., Rajput, M., Ranucci, G., Re, A., Rebber, H., Rebii, A., Ren, B., Rezinko, T., Ricci, B., Robens, M., Roche, M., Rodphai, N., Romani, A., Roth, C., Ruan, X., Rujirawat, S., Rybnikov, A., Sadovsky, A., Saggese, P., Salamanna, G., Sanfilippo, S., Sangka, A., Sanguansak, N., Sawangwit, U., Sawatzki, J., Sawy, F., Schever, M., Schuler, J., Schwab, C., Schweizer, K., Selivanov, D., Selyunin, A., Serafini, A., Settanta, G., Settimo, M., Shao, Z., Sharov, V., Shi, J., Shutov, V., Sidorenkov, A., Simkovic, F., Sirignano, C., Siripak, J., Sisti, M., Slupecki, M., Smirnov, M., Smirnov, O., Sogo-Bezerra, T., Songwadhana, J., Soonthornthum, B., Sotnikov, A., Sramek, O., Sreethawong, W., Stahl, A., Stanco, L., Stankevich, K., Stefanik, D., Steiger, H., Steinmann, J., Sterr, T., Stock, M. R., Strati, V., Studenikin, A., Sun, G. X., Sun, S. F., Sun, X. L., Sun, Y. J., Sun, Y. Z., Suwonjandee, N., Szelezniak, M., Tang, J., Tang, Q., Tang, X., Tietzsch, A., Tkachev, I., Triossi, A., Troni, G., Trzaska, W., Tuve, C., Ushakov, N., Waasen, S., Boom, J. Vanden, Vanroyen, G., Vassilopoulos, N., Vedin, V., Verde, G., Vialkov, M., Viaud, B., Volpe, C., Voronin, D., Votano, L., Walker, P., Wang, C., Wang, E., Wang, G., Wang, K. Y., Wang, L., Wang, M. F., Wang, S. G., Wang, W. S., Wang, X. Y., Wang, Y. G., Wang, Y. Q., Wang, Z. Y., Waqas, M., Watcharangkool, A., Wei, W., Wei, Y. D., Wiebusch, C., Wong, S. C. F., Wonsak, B., Wu, D., Wu, W. J., Wu, Z., Wurm, M., Wurtz, J., Wysotzki, C., Xi, Y. F., Xie, Y. G., Xu, B., Xu, C., Xu, D. L., Xu, F. R., Xu, H. K., Xu, J., Xu, M. H., Xu, Y., Yan, B. J., Yan, T., Yan, W. Q., Yan, X. B., Yan, Y. P., Yang, A. B., Yang, H., Yang, J., Yang, X. Y., Yang, Y., Yang, Y. F., Yasin, Z., Ye, J. X., Ye, Z. P., Yegin, U., Yermia, F., Yi, P. H., Yin, X. W., You, Z. Y., Yu, B. X., Yu, C. Y., Yu, C. X., Yu, M., Yu, X. H., Yuan, C. Z., Yuan, Y., Yuan, Z. X., Yuan, Z. Y., Zafar, N., Zambanini, A., Zeng, T. X., Zeng, Y. D., Zhang, G. Q., Zhang, H. Q., Zhang, J., Zhang, J. B., Zhang, P., Zhang, S., Zhang, T., Zhang, X. M., Zhang, Y., Zhang, Y. H., Zhang, Y. P., Zhao, F. Y., Zhao, R., Zhao, S. J., Zhao, T. C., Zheng, D. Q., Zheng, H., Zheng, M. S., Zheng, Y. H., Zhong, W. R., Zhou, J., Zhou, N., Zhou, S., Zhou, X., Zhu, J., Zhu, K. J., Zhuang, B., Zong, L., Rasco, B. C., Han, B. Y., Jeon, E. J., Jeong, Y., Jo, H. S., Kim, D. K., Kim, J. Y., Kim, J. G., Kim, Y. D., Ko, Y. J., Lee, H. M., Lee, M. H., Moon, C. S., Oh, Y. M., Park, H. K., Park, K. S., Seo, S. H., Siyeon, K., Sun, G. M., Yoon, Y. S., Yu, I., Borusinski, M. J., Dorrill, R., Druetzler, A., Learned, J., Li, V., Markoff, D., Maricic, J., Matsuno, S., Mumm, H. P., Nishimura, K., Irani, A., Pitt, M., Rasco, C., Thibodeau, B., Varner, G., Vogelaar, B., Wright, T., Andriamirado, M., Bass, C. D., Bergeron, D. E., Berish, D., Bowden, N. S., Brodsky, J. P., Bryan, C. D., Carr, R., Classen, T., Conant, A. J., Deichert, G., Dolinski, M. J., Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribarri, A., Gilbert, C. E., Grant, C., Hackett, B. T., Hansell, A. B., Ji, X., Jones, D. C., Kyzylova, O., Lane, C. E., Larosa, J., Lu, X., Mendenhall, M. P., Meyer, A. M., Milincic, R., Mitchell, I., Mueller, P. E., Nave, C., Neilson, R., Nikkel, J. A., Norcini, D., Nour, S., Palomino, J. L., Pushin, D. A., Romero-Romero, E., Surukuchi, P. T., Tyra, M. A., Varner, R. L., Venegas-Vargas, D., Weatherly, P. B., White, C., Wilhelmi, J., Woolverton, A., Zhang, A., Zhang, X., Choi, J. H., Jang, H. I., Jang, J. S., Jeon, S. H., Joo, K. K., Ju, K., Jung, D. E., Kim, J. H., Kim, S. B., Kim, S. Y., Kim, W., Kwon, E., Lee, D. H., Lee, H. G., Lim, I. T., Moon, D. H., Pac, M. Y., Seo, H., Seo, J. W., Shin, C. D., Yang, B. S., Yoo, J., Yoon, S. G., Yeo, I. S., Chang, C., Bergé, L., Broniatowski, A., Dumoulin, L., Giuliani, A., Chapellier, M., Marcillac, P., Marnieros, S., Olivieri, E., Poda, D., Calvo, M., Goupy, J., Monfardini, A., Arnaud, Q., Augier, C., Billard, J., Cazes, A., Colas, J., Filippini, J., Gascon, J., Jesus, M., Lattaud, H., Juillard, A., Salagnac, T., Soldner, T., Lubashevskiy, A., Yakushev, E., Rozov, S., Lamblin, J., Mom, B., Stutz, A., Formaggio, J. A., Mayer, D. W., Johnston, J., Harrington, P., Heine, S., Sibille, V., Chen, R., Figueroa-Feliciano, E., Ziqing, H., Hertel, S., Patel, P., Pinckney, D., Serafin, A., Shilcusky, A., Decheine, N., Palladino, K., Weber, S., Hirjibehedin, C., Akindele, O. A., Carman, L., Dazeley, S., Ford, M., Jovanovic, I., Sutanto, F., Zaitseva, N., Beaumont, W., Binet, S., Bolognino, I., Borg, J., Buridon, V., Chanal, H., Coupé, B., Crochet, P., Cussans, D., Roeck, A., Durand, D., Fallot, M., Galbinski, D., Gallego, S., Giot, L., Guillon, B., Henaff, D., Hayashida, S., Hosseini, B., Kalcheva, S., Lehaut, G., Michiels, I., Monteil, S., Newbold, D., Roy, N., Ryckbosch, D., Sfar, H. Rejeb, Simard, L., Vacheret, A., Vandierendonck, G., Dyck, S., Remortel, N., Vercaemer, S., Verstraeten, M., Weber, A., Yeresko, M., Bonhomme, A., Buck, C., Del Amo Sanchez, P., El Atmani, I., Labit, L., Letourneau, A., Lhuillier, D., Licciardi, M., Materna, T., Pessard, H., Rogly, R., Savu, V., Schoppmann, S., Vialat, M., Algora, A., Beloeuvre, A., Estienne, M., Kean, R., Porta, A., Tain, J. L., Sidelnik, I., Anderson, T., Askins, M., Bagdasarian, Z., Baldoni, A., Barna, A., Benson, T., Bergevin, M., Bernstein, A., Birrittella, B., Bogetic, S., Boissevain, J., Borusinki, J., Boyd, S., Brooks, T., Budsworth, Mat, Burns, J., Calle, M., Camilo, C., Carroll, A., Coleman, J., Collins, R., Connor, C., Cowen, D., Crow, B., Curry, J., Dalnoki-Veress, F., Danielson, D., Diwan, M., Dixon, S., Drakopoulou, L., Duron, J., Dye, S., Fargher, S., Fienberg, A., Fischer, V., Foster, R., Frankiewicz, Kat, Gamble, T., Gooding, D., Gokhale, S., Gregorio, R., Gribble, J., Griskevich, J., Hadley, D., He, J., Healey, K., Hecla, J., Holt, G., Jabbari, C., Jewkes, K., Kaiser, R., Keenan, M., Keener, P., Kneale, Liz, Kudryavtsev, V., Kunkle, P., Litchfield, P., Liu, X. Ran, Lynch, G., Malek, M., Marr-Laundrie, P., Masic, B., Mauger, C., Mccauley, N., Metelko, C., Mills, R., Mitra, A., Muheim, F., Mullen, A., Murphy, A., Needham, M., Neights, E., Ogren, K., Orebi Gann, G., Oxborough, L., Paling, S., Papatyi, A., Paulos, B., Pershing, T., Pickard, L., Quillin, S., Resoro, R., Richards, B., Sabarots, L., Scarff, A., Schnellbach, Yan-Jie, Scovell, P., Seitz, B., Shea, O., Shebalin, V., Smith, G., Smy, M., Song, H., Spooner, N., Stanton, C., Stone, O., Svoboda, R., Szoldos, S., Thompson, L., Thomson, F., Toth, C., Vagins, M., Berg, Rick, Ventura, S., Walsh, B., Webster, J., Weiss, M., Westphal, D., Wetstein, M., Wilson, T., Wilson, S., Wolcott, S., Wright, M., Berryman, J. M., Collar, J. I., Erlandson, A., Gariazzo, S., Garzelli, M. V., Giunti, C., Goldblum, B. L., Hayes, A., Hedges, S., Mariani, C., Minic, D., Mougeot, X., Naim, D., Newby, J., Ni, K., O Donnell, T., Ozturk, S., Périssé, L., Pestes, R., Sonzogni, A. A., Tabrizi, Z., Vivier, M., Institut de Physique Nucléaire d'Orsay (IPNO), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut Pluridisciplinaire Hubert Curien (IPHC), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique des 2 Infinis Irène Joliot-Curie (IJCLab), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Centre d'Etudes Nucléaires de Bordeaux Gradignan (CENBG), Université Sciences et Technologies - Bordeaux 1 (UB)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire Neutrino de Champagne Ardenne (LNCA - UMS 3263), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de physique subatomique et des technologies associées (SUBATECH), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-IMT Atlantique (IMT Atlantique), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-Nantes université - UFR des Sciences et des Techniques (Nantes univ - UFR ST), Nantes Université - pôle Sciences et technologie, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Sciences et technologie, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Centre de Sciences Nucléaires et de Sciences de la Matière (CSNSM), Cryogénie (NEEL - Cryo), Institut Néel (NEEL), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Hélium : du fondamental aux applications (NEEL - HELFA), Institut de Physique des 2 Infinis de Lyon (IP2I Lyon), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Laboratoire de Physique de Clermont (LPC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Clermont Auvergne (UCA), Laboratoire de physique corpusculaire de Caen (LPCC), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-École Nationale Supérieure d'Ingénieurs de Caen (ENSICAEN), Normandie Université (NU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de l'Accélérateur Linéaire (LAL), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut Laue-Langevin (ILL), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Département de Physique Nucléaire (ex SPhN) (DPHN), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, CHANDLER, CONNIE, CONUS, Daya Bay, JUNO, MTAS, NEOS, NuLat, PROSPECT, RENO, Ricochet, ROADSTR Near-Field Working Group, SoLid, Stereo, Valencia-Nantes TAGS, vIOLETA, WATCHMAN, and HEP, INSPIRE
- Subjects
High Energy Physics - Experiment (hep-ex) ,[PHYS.HEXP] Physics [physics]/High Energy Physics - Experiment [hep-ex] ,hep-ex ,neutrino: energy spectrum ,antineutrino: nuclear reactor ,[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex] ,FOS: Physical sciences ,neutrino: oscillation ,neutrino: nuclear reactor ,Particle Physics - Experiment ,neutrino: flux ,High Energy Physics - Experiment - Abstract
Nuclear reactors are uniquely powerful, abundant, and flavor-pure sources of antineutrinos that continue to play a vital role in the US neutrino physics program. The US reactor antineutrino physics community is a diverse interest group encompassing many detection technologies and many particle physics topics, including Standard Model and short-baseline oscillations, BSM physics searches, and reactor flux and spectrum modeling. The community's aims offer strong complimentary with numerous aspects of the wider US neutrino program and have direct relevance to most of the topical sub-groups composing the Snowmass 2021 Neutrino Frontier. Reactor neutrino experiments also have a direct societal impact and have become a strong workforce and technology development pipeline for DOE National Laboratories and universities. This white paper, prepared as a submission to the Snowmass 2021 community organizing exercise, will survey the state of the reactor antineutrino physics field and summarize the ways in which current and future reactor antineutrino experiments can play a critical role in advancing the field of particle physics in the next decade., Contribution to Snowmass 2021
- Published
- 2022
5. Joint Determination of Reactor Antineutrino Spectra from ²³⁵U and ²³⁹Pu Fission by Daya Bay and PROSPECT
- Author
-
An, F. P., Andriamirado, M., Balantekin, A. B., Band, H. R., Bass, C. D., Bergeron, D. E., Berish, D., Bishai, M., Blyth, S., Bowden, N. S., Bryan, C. D., Cao, G. F., Cao, J., Chang, J. F., Chang, Y., Chen, H. S., Chen, S. M., Chen, Y., Chen, Y. X., Cheng, J., Cheng, Z. K., Cherwinka, J. J., Chu, M. C., Classen, T., Conant, A. J., Cummings, J. P., Dalager, O., Deichert, G., Delgado, A., Deng, F. S., Ding, Y. Y., Diwan, M. V., Dohnal, T., Dolinski, M. J., Dolzhikov, D., Dove, J., Dvořák, M., Dwyer, D. A., Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribarri, A., Gallo, J. P., Gilbert, C. E., Gonchar, M., Gong, G. H., Gong, H., Grassi, M., Gu, W. Q., Guo, J. Y., Guo, L., Guo, X. H., Guo, Y. H., Guo, Z., Hackenburg, R. W., Hans, S., Hansell, A. B., He, M., Heeger, K. M., Heffron, B., Heng, Y. K., Hor, Y. K., Hsiung, Y. B., Hu, B. Z., Hu, J. R., Hu, T., Hu, Z. J., Huang, H. X., Huang, J. H., Huang, X. T., Huang, Y. B., Huber, P., Koblanski, J., Jaffe, D. E., Jayakumar, S., Jen, K. L., Ji, X. L., Ji, X. P., Johnson, R. A., Jones, D. C., Kang, L., Kettell, S. H., Kohn, S., Kramer, M., Kyzylova, O., Lane, C. E., Langford, T. J., LaRosa, J., Lee, J., Lee, J. H. C., Lei, R. T., Leitner, R., Leung, J. K. C., Li, F., Li, H. L., Li, J. J., Li, Q. J., Li, R. H., Li, S., Li, S. C., Li, W. D., Li, X. N., Li, X. Q., Li, Y. F., Li, Z. B., Liang, H., Lin, C. J., Lin, G. L., Lin, S., Ling, J. J., Link, J. M., Littenberg, L., Littlejohn, B. R., Liu, J. C., Liu, J. L., Liu, J. X., Lu, C., Lu, H. Q., Lu, X., Luk, K. B., Ma, B. Z., Ma, X. B., Ma, X. Y., Ma, Y. Q., Mandujano, R. C., Maricic, J., Marshall, C., McDonald, K. T., McKeown, R. D., Mendenhall, M. P., Meng, Y., Meyer, A. M., Milincic, R., Mueller, P. E., Mumm, H. P., Napolitano, J., Naumov, D., Naumova, E., Neilson, R., Nguyen, T. M. T., Nikkel, J. A., Nour, S., Ochoa-Ricoux, J. P., Olshevskiy, A., Palomino, J. L., Pan, H.-R., Park, J., Patton, S., Peng, J. C., Pun, C. S. J., Pushin, D. A., Qi, F. Z., Qi, M., Qian, X., Raper, N., Ren, J., Morales Reveco, C., Rosero, R., Roskovec, B., Ruan, X. C., Searles, M., Steiner, H., Sun, J. L., Surukuchi, P. T., Tmej, T., Treskov, K., Tse, W.-H., Tull, C. E., Tyra, M. A., Varner, R. L., Venegas-Vargas, D., Viren, B., Vorobel, V., Wang, C. H., Wang, J., Wang, M., Wang, N. Y., Wang, R. G., Wang, W., Wang, X., Wang, Y., Wang, Y. F., Wang, Z., Wang, Z. M., Weatherly, P. B., Wei, H. Y., Wei, L. H., Wen, L. J., Whisnant, K., White, C., Wilhelmi, J., Wong, H. L. H., Woolverton, A., Worcester, E., Wu, D. R., Wu, F. L., Wu, Q., Wu, W. J., Xia, D. M., Xie, Z. Q., Xing, Z. Z., Xu, H. K., Xu, J. L., Xu, T., Xue, T., Yang, C. G., Yang, L., Yang, Y. Z., Yao, H. F., Ye, M., Yeh, M., Young, B. L., Yu, H. Z., Yu, Z. Y., Yue, B. B., Zavadskyi, V., Zeng, S., Zeng, Y., Zhan, L., Zhang, C., Zhang, F. Y., Zhang, H. H., Zhang, J. W., Zhang, Q. M., Zhang, S. Q., Zhang, X., Zhang, X. T., Zhang, Y. M., Zhang, Y. X., Zhang, Y. Y., Zhang, Z. J., Zhang, Z. P., Zhang, Z. Y., Zhao, J., Zhao, R. Z., Zhou, L., Zhuang, H. L., and Zou, J. H.
- Abstract
A joint determination of the reactor antineutrino spectra resulting from the fission of ²³⁵U and ²³⁹Pu has been carried out by the Daya Bay and PROSPECT Collaborations. This Letter reports the level of consistency of ²³⁵U spectrum measurements from the two experiments and presents new results from a joint analysis of both data sets. The measurements are found to be consistent. The combined analysis reduces the degeneracy between the dominant ²³⁵U and ²³⁹Pu isotopes and improves the uncertainty of the ²³⁵U spectral shape to about 3%. The ²³⁵U and ²³⁹Pu antineutrino energy spectra are unfolded from the jointly deconvolved reactor spectra using the Wiener-SVD unfolding method, providing a data-based reference for other reactor antineutrino experiments and other applications. This is the first measurement of the ²³⁵U and ²³⁹Pu spectra based on the combination of experiments at low- and highly enriched uranium reactors.
- Published
- 2022
6. Physics Opportunities with PROSPECT-II
- Author
-
Andriamirado, M., Balantekin, A. B., Bass, C. D., Bergeron, D. E., Bernard, E., Bowden, N. S., Bryan, C. D., Carr, R., Classen, T., Conant, A. J., Deichert, G., Delgado, A., Diwan, M. V., Dolinski, M. J., Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribari, A., Gilbert, C. E., Gokhale, S., Grant, C., Hans, S., Hansell, A. B., Heeger, K. M., Heffron, B., Jaffe, D. E., Jayakumar, S., Ji, X., Jones, D. C., Koblanski, J., Kunkle, P., Kyzylova, O., Lane, C. E., Langford, T. J., LaRosa, J., Littlejohn, B. R., Lu, X., Maricic, J., Mendenhall, M. P., Meyer, A. M., Milincic, R., Mueller, P. E., Mumm, H. P., Napolitano, J., Neilson, R., Nikkel, J. A., Nour, S., Palomino, J. L., Pushin, D. A., Qian, X., Roca, C., Rosero, R., Searles, M., Surukuchi, P. T., Sutanto, F., Tyra, M. A., Varner, R. L., Venegas-Vargas, D., Weatherly, P. B., Wilhelmi, J., Woolverton, A., Yeh, M., Zhang, C., and Zhang, X.
- Subjects
High Energy Physics - Experiment (hep-ex) ,High Energy Physics::Phenomenology ,FOS: Physical sciences ,High Energy Physics::Experiment ,Nuclear Experiment (nucl-ex) ,Nuclear Experiment ,High Energy Physics - Experiment - Abstract
The PROSPECT experiment has substantially addressed the original 'Reactor Antineutrino Anomaly' by performing a high-resolution spectrum measurement from an enriched compact reactor core and a reactor model-independent sterile neutrino oscillation search based on the unique spectral distortions the existence of eV$^2$-scale sterile neutrinos would impart. But as the field has evolved, the current short-baseline (SBL) landscape supports many complex phenomenological interpretations, establishing a need for complementary experimental approaches to resolve the situation. While the global suite of SBL reactor experiments, including PROSPECT, have probed much of the sterile neutrino parameter space, there remains a large region above 1 eV$^2$ that remains unaddressed. Recent results from BEST confirm the Gallium Anomaly, increasing its significance to $\sim 5\sigma$, with sterile neutrinos providing a possible explanation of this anomaly. Separately, the MicroBooNE exclusion of electron-like signatures causing the MiniBooNE low-energy excess does not eliminate the possibility of sterile neutrinos as an explanation. Focusing specifically on the future use of reactors as a neutrino source for beyond-the-standard-model physics and applications, higher-precision spectral measurements still have a role to play. These recent results have created a confusing landscape which requires new data to disentangle the seemingly contradictory measurements. To directly probe $\overline{\nu}_{e}$ disappearance from high $\Delta m^2$ sterile neutrinos, the PROSPECT collaboration proposes to build an upgraded and improved detector, PROSPECT-II. It features an evolutionary detector design which can be constructed and deployed within one year and have impactful physics with as little as one calendar year of data., Comment: contribution to Snowmass 2021
- Published
- 2022
7. Joint Measurement of the $^{235}$U Antineutrino Spectrum by Prospect and Stereo
- Author
-
Almazán, H., Andriamirado, M., Balantekin, A. B., Band, H. R., Bass, C. D., Bergeron, D. E., Bernard, L., Blanchet, A., Bonhomme, A., Bowden, N. S., Bryan, C. D., Buck, C., Classen, T., Conant, A. J., Deichert, G., Sanchez, P. del Amo, Delgado, A., Diwan, M. V., Dolinski, M. J., Atmani, I. El, Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribarri, A., Gilbert, C. E., Hans, S., Hansell, A. B., Heeger, K. M., Heffron, B., Jaffe, D. E., Jayakumar, S., Ji, X., Jones, D. C., Koblanski, J., Kyzylova, O., Labit, L., Lamblin, J., Lane, C. E., Langford, T. J., LaRosa, J., Letourneau, A., Lhuillier, D., Licciardi, M., Lindner, M., Littlejohn, B. R., Lu, X., Maricic, J., Materna, T., Mendenhall, M. P., Meyer, A. M., Milincic, R., Mueller, P. E., Mumm, H. P., Napolitano, J., Neilson, R., Nikkel, J. A., Nour, S., Palomino, J. L., Pessard, H., Pushin, D. A., Qian, X., Réal, J. -S., Ricol, J. -S., Roca, C., Rogly, R., Rosero, R., Salagnac, T., Savu, V., Schoppmann, S., Searles, M., Sergeyeva, V., Soldner, T., Stutz, A., Surukuchi, P. T., Tyra, M. A., Varner, R. L., Venegas-Vargas, D., Vialat, M., Weatherly, P. B., White, C., Wilhelmi, J., Woolverton, A., Yeh, M., Zhang, C., Zhang, X., Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP ), Université Grenoble Alpes (UGA), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire d'Annecy de Physique des Particules (LAPP), Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Savoie Mont Blanc (USMB [Université de Savoie] [Université de Chambéry])-Centre National de la Recherche Scientifique (CNRS), Institut Laue-Langevin (ILL), ILL, Prospect, and Stereo
- Subjects
antineutrino: spectrum ,energy spectrum ,FOS: Physical sciences ,[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex] ,antineutrino: energy ,High Energy Physics - Experiment ,uranium ,High Energy Physics - Experiment (hep-ex) ,[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex] ,spectral ,STEREO ,nuclear reactor ,Nuclear Experiment (nucl-ex) ,Nuclear Experiment - Abstract
International audience; The PROSPECT and STEREO collaborations present a combined measurement of the pure U235 antineutrino spectrum, without site specific corrections or detector-dependent effects. The spectral measurements of the two highest precision experiments at research reactors are found to be compatible with χ2/ndf=24.1/21, allowing a joint unfolding of the prompt energy measurements into antineutrino energy. This ν¯e energy spectrum is provided to the community, and an excess of events relative to the Huber model is found in the 5–6 MeV region. When a Gaussian bump is fitted to the excess, the data-model χ2 value is improved, corresponding to a 2.4σ significance.
- Published
- 2021
8. Accuracy of digital mRNA profiling of oesophageal biopsies as a novel diagnostic approach to eosinophilic oesophagitis
- Author
-
Lexmond, W. S., Hu, L., Pardo, M., Heinz, N., Rooney, K., LaRosa, J., Dehlink, E., Fiebiger, E., and Nurko, S.
- Published
- 2015
- Full Text
- View/download PDF
9. A new Certified Reference Material for radionuclides in Irish sea sediment (IAEA-385)
- Author
-
Pham, M.K., Sanchez-Cabeza, J.A., Povinec, P.P., Andor, K., Arnold, D., Benmansour, M., Bikit, I., Carvalho, F.P., Dimitrova, K., Edrev, Z.H., Engeler, C., Fouche, F.J., Garcia-Orellana, J., Gascó, C., Gastaud, J., Gudelis, A., Hancock, G., Holm, E., Legarda, F., Ikäheimonen, T.K., Ilchmann, C., Jenkinson, A.V., Kanisch, G., Kis-Benedek, G., Kleinschmidt, R., Koukouliou, V., Kuhar, B., LaRosa, J., Lee, S.-H., LePetit, G., Levy-Palomo, I., Liong Wee Kwong, L., Llauradó, M., Maringer, F.J., Meyer, M., Michalik, B., Michel, H., Nies, H., Nour, S., Oh, J.-S., Oregioni, B., Palomares, J., Pantelic, G., Pfitzner, J., Pilvio, R., Puskeiler, L., Satake, H., Schikowski, J., Vitorovic, G., Woodhead, D., and Wyse, E.
- Published
- 2008
- Full Text
- View/download PDF
10. Use of thin collodion films to prevent recoil-ion contamination of alpha-spectrometry detectors
- Author
-
Inn, K. G. W., Hall, E., Woodward, IV, J. T., Stewart, B., Pollanen, R., Selvig, L., Turner, S., Outola, I., Nour, S., Kurosaki, H., LaRosa, J., Schultz, M., Lin, Z., Yu, Z., and McMahon, C.
- Published
- 2008
- Full Text
- View/download PDF
11. Improved Short-Baseline Neutrino Oscillation Search and Energy Spectrum Measurement with the PROSPECT Experiment at HFIR
- Author
-
Andriamirado, M., Balantekin, A. B., Band, H. R., Bass, C. D., Bergeron, D. E., Berish, D., Bowden, N. S., Brodsky, J. P., Bryan, C. D., Classen, T., Conant, A. J., Deichert, G., Diwan, M. V., Dolinski, M. J., Erickson, A., Foust, B. T., Gaison, J. K., Galindo-Uribarri, A., Gilbert, C. E., Goddard, B. W., Hackett, B. T., Hans, S., Hansell, A. B., Heeger, K. M., Heffron, B., Jaffe, D. E., Ji, X., Jones, D. C., Kyzylova, O., Lane, C. E., Langford, T. J., LaRosa, J., Littlejohn, B. R., Lu, X., Maricic, J., Mendenhall, M. P., Meyer, A. M., Milincic, R., Mitchell, I., Mueller, P. E., Mumm, H. P., Napolitano, J., Nave, C., Neilson, R., Nikkel, J. A., Norcini, D., Nour, S., Palomino, J. L., Pushin, D. A., Qian, X., Romero-Romero, E., Rosero, R., Surukuchi, P. T., Tyra, M. A., Varner, R. L., Venegas-Vargas, D., Weatherly, P. B., White, C., Wilhelmi, J., Woolverton, A., Yeh, M., Zhang, A., Zhang, C., and Zhang, X.
- Subjects
Physics ,Fission products ,Sterile neutrino ,010308 nuclear & particles physics ,Oscillation ,Anomaly (natural sciences) ,FOS: Physical sciences ,Oak Ridge National Laboratory ,01 natural sciences ,7. Clean energy ,Spectral line ,High Energy Physics - Experiment ,Nuclear physics ,High Energy Physics - Experiment (hep-ex) ,13. Climate action ,0103 physical sciences ,High Energy Physics::Experiment ,Nuclear Experiment (nucl-ex) ,010306 general physics ,Neutrino oscillation ,Nuclear Experiment ,High Flux Isotope Reactor - Abstract
We present a detailed report on sterile neutrino oscillation and U-235 antineutrino energy spectrum measurement results from the PROSPECT experiment at the highly enriched High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory. In 96 calendar days of data taken at an average baseline distance of 7.9 m from the center of the 85 MW HFIR core, the PROSPECT detector has observed more than 50,000 interactions of antineutrinos produced in beta decays of U-235 fission products. New limits on the oscillation of antineutrinos to light sterile neutrinos have been set by comparing the detected energy spectra of ten reactor-detector baselines between 6.7 and 9.2 meters. Measured differences in energy spectra between baselines show no statistically significant indication of antineutrinos to sterile neutrino oscillation and disfavor the Reactor Antineutrino Anomaly best-fit point at the 2.5$\sigma$ confidence level. The reported U-235 antineutrino energy spectrum measurement shows excellent agreement with energy spectrum models generated via conversion of the measured U-235 beta spectrum, with a $\chi^2$/DOF of 31/31. PROSPECT is able to disfavor at 2.4$\sigma$ confidence level the hypothesis that U-235 antineutrinos are solely responsible for spectrum discrepancies between model and data obtained at commercial reactor cores. A data-model deviation in PROSPECT similar to that observed by commercial core experiments is preferred with respect to no observed deviation, at a 2.2$\sigma$ confidence level., Comment: 42 pages, 52 Figures. Submitted to Phys. Rev. D. Supplementary Material Included
- Published
- 2020
12. Relationship between postprandial metabolomics and colon motility in children with constipation
- Author
-
Rodriguez, L., Roberts, L. D., LaRosa, J., Heinz, N., Gerszten, R., Nurko, S., and Goldstein, A. M.
- Published
- 2013
- Full Text
- View/download PDF
13. Combined procedure for the determination of90Sr,241Am and Pu radionuclides in soil samples
- Author
-
Moreno, J., Vajda, N., Danesi, P. R., Larosa, J. J., Zeiller, E., and Sinojmeri, M.
- Published
- 1997
- Full Text
- View/download PDF
14. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
- Author
-
Fulcher, J, Mihaylova, B, O'Connell, R, Emberson, J, Blackwell, L, Reith, C, Koren, M, Tonkin, A, Ridker, P, Barnes, E, Ford, I, Kean, S, Trompet, S, Macfarlane, P, Cannon, C, Pedersen, TR, Wilhelmsen, L, LaRosa, J, Packard, C, Robertson, M, Young, R, Tobert, J, Flather, M, Goto, S, Kastelein, J, Newman, C, Shear, C, Varigos, J, White, H, Armitage, J, Davies, K, Halls, H, Harper, C, Herrington, W, Holland, L, Kirby, A, Oconnell, R, Preiss, D, Spata, E, Wilson, K, Lonn, E, Wanner, C, Koenig, W, Gotto, A, Kjekshus, J, Yusuf, S, Collins, R, Simes, J, Baigent, C, Keech, A, De Lemos, J, Braunwald, E, Blazing, M, Murphy, S, Downs, JR, Clearfield, M, Holdaas, H, Gordon, D, Davis, B, Dahlof, B, Poulter, N, Sever, P, Knopp, RH, Fellstrom, B, Jardine, A, Schmieder, R, Zannad, F, Colhoun, HM, Betteridge, DJ, Durrington, PN, Hitman, GA, Fuller, J, Neil, A, Sacks, F, Moye, L, Pfeffer, M, Hawkins, CM, Wedel, H, Wikstrand, J, Krane, V, Tavazzi, L, Maggioni, A, Marchioli, R, Tognoni, G, Franzosi, MG, Bowman, L, Landray, MJ, Parish, S, Peto, R, Sleight, P, Ridker, PM, Macmahon, S, Marschner, I, Shaw, J, Serruys, PW, Nakamura, H, Knatterud, G, Furberg, C, Byington, R, Sattar, N, and Jukema, JW
- Subjects
medicine.medical_specialty ,Statin ,medicine.drug_class ,Atorvastatin ,030204 cardiovascular system & hematology ,ATORVASTATIN ,PURLs® ,Rate ratio ,Article ,03 medical and health sciences ,0302 clinical medicine ,Medicine, General & Internal ,Risk Factors ,Internal medicine ,General & Internal Medicine ,medicine ,Humans ,Rosuvastatin ,CORONARY-HEART-DISEASE ,030212 general & internal medicine ,Myocardial infarction ,ROSUVASTATIN ,Stroke ,ELDERLY-PATIENTS ,Aged ,Randomized Controlled Trials as Topic ,Aged, 80 and over ,RISK ,Science & Technology ,Cholesterol Treatment Trialists' Collaboration ,Vascular disease ,business.industry ,CHOLESTEROL ,Age Factors ,General Medicine ,11 Medical And Health Sciences ,medicine.disease ,R1 ,3. Good health ,LOWERING THERAPY ,Regimen ,MYOCARDIAL-INFARCTION ,Cardiovascular Diseases ,CARDIOVASCULAR-DISEASE ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,business ,PRIMARY PREVENTION ,Life Sciences & Biomedicine ,medicine.drug - Abstract
Background: Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.Methods: In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56–60 years, 61–65 years, 66–70 years, 71–75 years, and older than 75 years). We estimated effects on major vascular events (ie, major coronary events, strokes, and coronary revascularisations), cause-specific mortality, and cancer incidence as the rate ratio (RR) per 1·0 mmol/L reduction in LDL cholesterol. We compared proportional risk reductions in different age subgroups by use of standard χ2 tests for heterogeneity when there were two groups, or trend when there were more than two groups.Findings: 14 483 (8%) of 186 854 participants in the 28 trials were older than 75 years at randomisation, and the median follow-up duration was 4·9 years. Overall, statin therapy or a more intensive statin regimen produced a 21% (RR 0·79, 95% CI 0·77–0·81) proportional reduction in major vascular events per 1·0 mmol/L reduction in LDL cholesterol. We observed a significant reduction in major vascular events in all age groups. Although proportional reductions in major vascular events diminished slightly with age, this trend was not statistically significant (ptrend=0·06). Overall, statin or more intensive therapy yielded a 24% (RR 0·76, 95% CI 0·73–0·79) proportional reduction in major coronary events per 1·0 mmol/L reduction in LDL cholesterol, and with increasing age, we observed a trend towards smaller proportional risk reductions in major coronary events (ptrend=0·009). We observed a 25% (RR 0·75, 95% CI 0·73–0·78) proportional reduction in the risk of coronary revascularisation procedures with statin therapy or a more intensive statin regimen per 1·0 mmol/L lower LDL cholesterol, which did not differ significantly across age groups (ptrend=0·6). Similarly, the proportional reductions in stroke of any type (RR 0·84, 95% CI 0·80–0·89) did not differ significantly across age groups (ptrend=0·7). After exclusion of four trials which enrolled only patients with heart failure or undergoing renal dialysis (among whom statin therapy has not been shown to be effective), the trend to smaller proportional risk reductions with increasing age persisted for major coronary events (ptrend=0·01), and remained non-significant for major vascular events (ptrend=0·3). The proportional reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease (ptrend=0·2), but appeared smaller among older than among younger individuals not known to have vascular disease (ptrend=0·05). We found a 12% (RR 0·88, 95% CI 0·85–0·91) proportional reduction in vascular mortality per 1·0 mmol/L reduction in LDL cholesterol, with a trend towards smaller proportional reductions with older age (ptrend=0·004), but this trend did not persist after exclusion of the heart failure or dialysis trials (ptrend=0·2). Statin therapy had no effect at any age on non-vascular mortality, cancer death, or cancer incidence.Interpretation: Statin therapy produces significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive vascular disease. This limitation is now being addressed by further trials.Funding: Australian National Health and Medical Research Council, National Institute for Health Research Oxford Biomedical Research Centre, UK Medical Research Council, and British Heart Foundation.
- Published
- 2019
15. Analysis of actinides in the primary coolant of a WWER-440 type reactor
- Author
-
Vajda, N., Larosa, J., Pintér, T., Keömley, G., Bódizs, D., and Molnár, Zs.
- Published
- 1993
- Full Text
- View/download PDF
16. IAEA Programme of natural matrix reference materials for the determination of radionuclides
- Author
-
Strachnov, V., Valkovic, V., LaRosa, J., Dekner, R., and Zeisler, R.
- Published
- 1993
- Full Text
- View/download PDF
17. Evolocumab and clinical outcomes in patients with cardiovascular disease
- Author
-
Sabatine, Marc S., Giugliano, Robert P., Keech, Anthony C., Honarpour, Narimon, Wiviott, Stephen D., Murphy, Sabina A., Kuder, Julia F., Wang, Huei, Liu, Thomas, Wasserman, Scott M., Sever, Peter S., Pedersen, Fish MP, Terje R., Abrahamsen, Te, Im, K, Kanevsky, E, Bonaca, Mp, Lira Pineda, A, Hanlon, K, Knusel, B, Somaratne, R, Kurtz, C, Scott, R, Accini Mendoza JL, Amerena, J, Badariene, J, Burgess, L, Ceska, R, Charng, Mj, Choi, D, Cobos, Jl, Dan, Ga, De Ferrari GM, Deedwania, Pc, Chopra, Vk, Erglis, A, Ezhov, Mv, Ferreira, J, Filipová, S, Gaciong, Za, Pasierski, T, Georgiev, Bg, Gonzalez-Galvez, G, Gouni-Berthold, I, Schäufele, T, Hirayama, A, Huber, K, Rammer, M, Kjaerulf Jensen, H, Wermuth, S, Jiang, L, Jukema, Jw, Kraydashenko, O, Leiter, La, Lewis, Bs, López-Miranda, J, Lorenzatti, Aj, Mach, F, Mcadam, B, Nilsson, L, Olsson, Å, Rallidis, L, Rogelio, Gg, Kerr Saraiva JF, Scheen, A, Schiele, F, Scott, Rs, Connolly, D, Siu, Cw, Tay, L, Thorgeirsson, G, Tikkanen, Mj, Tokgozoglu, Sl, Toth, K, Viigimaa, M, Wan Ahmad WA, Hennekens, Ch, Andreotti, F, Baigent, C, Brown, Wv, Davis, Br, Newcomer, Jw, Wood, Sk, Larosa, J, Ansell, B, Olsson, A, Lowe, C, Zahn, L, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Mackinnon, I, Vogel, Dr, Leon de la Fuente, R, Perna, E, Amuchastegui, M, Pacora, F, Hershson, A, Blumberg, E, Glenny, Ja, Colombo, H, Cuadrado, Ja, Nicolosi, L, Rojas, Cg, Ulla, Mr, Hasbani, Eg, Cuneo, C, Lopez Santi RG, Sanabria, Hd, Hrabar, A, Lozada, A, Begg, A, Lehman, S, Wittert, G, Juergens, C, Kostner, K, Beltrame, J, Simpson, R, Sinhal, A, Adams, M, Kritharides, L, Roberts Thomson, P, Cross, D, Thompson, P, Van Gaal, W, Cox, N, Farshid, A, Hammett, C, Garrahy, P, Prasan, A, Horrigan, M, Ebenbichler, C, Hanusch, U, Prager, R, Schernthaner, G, Luger, A, Siostrzonek, P, Toplak, H, Bergler-Klein, J, Paulweber, B, Sinzinger, H, Buysschaert, I, Thoeng, J, Vandekerckhove, H, Catez, E, Verheye, S, Descamps, O, Hoffer, E, Wollaert, B, Chenu, P, van de Borne, P, De Meulemeester, M, Friart, A, Charlier, F, De Raedt, H, Rietzschel, E, Roelandt, R, Lalmand, J, Tavares Russo LA, Reis, G, Duarte Barbosa EC, Vidotti, Mh, Fernandes Manenti ER, Dutra, O, Leaes, Pe, Rech, Rl, Bertolim Precoma, D, Nicolau, Jc, Amoedo, R, Eliaschewitz, Fg, Pereira, A, Kurtz Lisboa HR, Soares Piegas, L, Cunha Borges JL, Ferreira Rossi PR, Pimentel Filho, P, Bodanese, Lc, de Sa Cunha, R, Moura Jorge JC, Ardito, Wr, Barroso de Souza WK, Hissa, M, Izar, Mc, Manolova, A, Kitova, L, Kinova, E, Tzekova, M, Velchev, V, Tarnovska-Kadreva, R, Gotchev, D, Petrov, I, Raev, D, Trendafilova-Lazarova, D, Yotov, Y, Lazov, P, Rahimi, S, St Amour, E, Constance, C, Pesant, Y, Hess, A, Anderson, T, Sussex, B, Henein, S, Tsoukas, G, Pandey, As, Bergeron, J, Hart, R, Gosselin, G, Chehayeb, R, Hamet, P, Hartleib, M, Mukherjee, A, Halperin, F, Petrella, R, Bhargava, R, Lonn, E, Sabbah, E, Bata, I, Cha, J, Gaudet, D, Chapman, K, Murthy, D, Nigro, F, Rupka, D, Gossard, D, Gupta, M, Dowell, A, Mansour, S, Baass, A, Geadah, C, Huynh, T, Peterson, S, Poirier, P, Sabe-Affaki, G, Vertes, G, Crowley, D, Duchesne, L, Pincetti Jofre CP, Potthoff Cardenas, S, Conejeros Kindel, C, Saavedra Gajardo VA, Lanas Zanetti, F, Sepulveda Varela PA, Stockins Fernandez BA, Li, W, Li, D, Zhao, S, Li, Z, Wang, J, Yang, Y, Zhang, L, Yang, P, Zhang, X, Huang, H, Xue, L, Zheng, Z, Huang, W, Dai, H, Su, H, Zeng, X, Zheng, Y, Tang, Y, Yao, Z, Sun, Y, Du, Y, Ge, Z, Yan, J, Chen, X, Liu, F, Pei, H, Yang, X, Cui, H, Gu, Y, Yang, Z, Li, J, Lian, Y, Cui, Y, Wang, D, Jiang, J, Li, X, Chen, J, Mo, Z, Xu, P, He, Y, Zhou, C, Qu, P, Zhu, Y, Liu, Y, Shen, X, Gao, X, Terront Lozano MA, Moncada Corredor MA, Hernandez Triana, E, Botero Lopez, R, Coronel Arroyo JA, Quintero Baiz AE, Sanchez Vallejo, G, Arana Londoño, C, Molina de Salazar DI, Castellanos Bueno, R, Manzur Jattin, F, Cure Cure CA, Sotomayor Herazo, A, Spinar, J, Hala, T, Machkova, M, Klimsa, Z, Polasek, R, Jerabek, O, Kazdera, P, Pozdisek, Z, Vaclavik, J, Frana, P, Elbl, L, Kucera, D, Kryza, R, Malecha, J, Reichert, P, Sochor, K, Ludka, O, Kellnerova, I, Peterka, K, Zidkova, E, Cech, V, Brabec, T, Fiserova, N, Kvasnicka, J, Rosolova, H, Nemecek, E, Adamkova, V, Dunaj, M, Pojsl, S, Cepelak, M, Podpera, I, Kuchar, L, Rysava, D, Burianova, H, Spinarova, L, Skrobakova, J, Charvat, J, Homza, M, Zemanek, J, Koleckar, P, Karen, I, Krupicka, J, Blaha, V, Matuska, J, Brotanek, J, Cifkova, R, Kuchar, R, Vomacka, Z, Kosek, Z, Hulinsky, V, Krejcova, H, Kuchar, J, Jelinek, Z, Jelinek, P, Markdanner Lindgren, L, Saetre Lihn, A, Korsgaard Thomsen, K, Bronnum-Schou, J, Nielsen, H, Nielsen, T, Egstrup, K, Klausen, Ic, Mickley, H, Hove, J, Jeppesen, J, Melchior, T, Schmidt, Eb, Valter, I, Rosenthal, A, Kaik, J, Kork, A, Alt, I, Strand, J, Nieminen, S, Kahri, J, Suomi, J, Nyman, K, Strandberg, Te, Piippo, T, Savolainen, M, Vikman, S, Pucheu, Y, Cariou, B, Henry, P, Ferrari, E, Montalescot, G, Ferrieres, J, Roubille, F, Bonnet, B, Angoulvant, D, Range, G, Bammert, A, Delarche, N, Mariat, C, Cayla, G, Durlach, V, Coisne, D, Paillard, F, Rouzier, R, Goralski, M, Khanoyan, P, Cottin, Y, Ziegler, O, Khalife, K, Le Corvoisier, P, Motreff, P, Spaulding, C, Vanbelle, E, Bourhaial, H, Opitz, C, Kahrmann, G, Contzen, C, Appel, K, Schenkenberger, I, Rinke, A, Trenk, D, Maus, O, Karakas, M, Hanefeld, M, Darius, H, Hetzel, G, Münzel, T, Wöhrle, J, Stawowy, P, Marten, I, Isermann, B, Kast, P, Vorpahl, M, Bosiljanoff, P, Hengstenberg, C, Kassner, U, Salbach, P, Fischer, M, Steiner, S, Wagner, S, Kraatz, U, von Hodenberg, E, Weyland, K, Mantas, I, Tziakas, D, Bousboulas, S, Patsilinakos, S, Mertzanos, G, Panagoulis, C, Bilianou, H, Skoumas, I, Elisaf, M, Manolis, A, Moschos, N, Kochiadakis, G, Ntaios, G, Richter, D, Athyros, V, Kolovou, G, Danias, P, Melidonis, A, Fan, Kyy, Siu, Sc, Hornyik, A, Lakatos, F, Zilahi, Z, Nagy, K, Laszlo, Z, Peterfai, E, Lupkovics, G, Andreka, P, Merkely, B, Herczeg, B, Piros, Ga, Salamon, C, Mark, L, Papp, A, Szakal, I, Edes, I, Mohacsi, A, Tomcsanyi, J, Hajko, E, Nagy, A, Papp, E, Kiss, R, Karadi, I, Sigurdsson, A, Jain, A, Pai, R, Kothiwale, V, Kulkarni, G, Mahajan, A, Aggarwal, S, Mehta, V, Rajadhyaksha, G, Joshi, A, Khandait, V, Parmar, M, Tyagi, S, Airody Govinda, R, Dwivedi, Sk, Parikh, K, Pothineni, Rb, Solanki, B, O’Donnell, M, Crean, P, Barton, J, Shechter, M, Shotan, A, Klutstein, M, Chorin, E, Gavish, D, Kracoff, O, Atar, S, Rigler, S, Hasin, Y, Schiff, E, Merlini, P, Rapezzi, C, Pirro, M, Gonnelli, S, Floresta, Am, Mennuni, M, Ardissino, D, Senni, M, Marenzi, G, Marcucci, R, Sampietro, T, Cosmi, F, Perrone Filardi, P, De Caterina, R, Fedele, Francesco, Moretti, L, Biasucci, Lm, Ferri, C, Go, Y, Kiyosue, A, Higashi, Y, Tokunaga, T, Kawasaki, T, Sakagami, S, Namba, S, Saku, K, Oku, K, Arakawa, T, Iida, H, Nakamura, Y, Yamamoto, K, Hata, Y, Katsuda, Y, Koga, Y, Shimizu, M, Uehara, H, Kajiyama, S, Okamoto, H, Shinozaki, T, Fujino, Y, Funazaki, T, Higa, N, Kaigawa, K, Koike, A, Nakane, H, Sato, K, Satoh, Y, Shirasawa, K, Sugino, H, Tanabe, J, Uemura, O, Yoshimichi, G, Akai, A, Himeno, H, Inage, T, Inoko, M, Kadokami, T, Noguchi, Y, Yamashita, K, Yasumura, Y, Yuge, M, Hosokawa, S, Kawamitsu, K, Kozuma, K, Matsuo, H, Nakashima, E, Okada, M, Wada, A, Yokoya, K, Iwade, K, Kawabata, K, Tanno, H, Ako, J, Fujita, H, Izumiya, Y, Kanno, M, Nunohiro, T, Ohmura, H, Ueno, T, Kakurina, N, Jasinkevica, I, Stukena, I, Veze, I, Eglite, R, Teterovska, D, Sime, I, Strazdiene, V, Venceviciene, L, Gustiene, O, Radzeviciene-Jurgute, R, Kucinskiene, A, Maskon, O, Lee, Cy, Erng, T, Gan, Hw, Mohamed Yusof AK, Ramanathan, Gl, Liew, H, Lopez Alvarado, A, Nevarez Ruiz LA, De los Rios Ibarra MO, Bazzoni Ruiz AE, Ramos Lopez GA, Llamas Esperon GA, De la Peña Topete GDJ, Violante Ortiz RM, Illescas Diaz JJ, Leon Gonzalez, S, Sanchez Diaz CJ, Mendez Machado GF, Venegas Carrillo LA, Aldrete Velasco JA, Cardona Muñoz EG, Leiva Pons JL, Perez Alva JC, van der Zwaan, C, Oomen, A, van de Wal, R, Magro, M, Boswijk, D, Janus, C, Groutars, R, Tonino, W, Cornel, Jh, Oude Ophuis, A, Troquay, R, Liem, A, Westendorp, I, Van Hessen, M, Lok, D, De Nooijer, C, Den Hartog, F, Van Beek, E, Bendermacher, P, Jansen, R, Römer, T, Rensing, B, Hersbach, F, Herrman, J, Ladyjanskaia, G, Karalis, I, Linssen, G, Bokern, M, Visman, A, Kooij, A, Monajemi, H, Lieverse, A, Baker, J, Tie, S, Risberg, K, Hysing, J, Pedersen, T, Hoivik, Ho, Norheim, P, Solnor, L, Hovland, A, Kjaernli, T, Jocson, G, Coching, Rm, Batalla, E, Go, A, Habaluyas, R, Barcinas, R, Sy, Ra, Estepar, Ra, Germar, A, Trebacz, J, Szymkowiak, K, Wnetrzak-Michalska, R, Kopaczewski, J, Przekwas-Jaruchowska, M, Kania, G, Zabowka, M, Mirek-Bryniarska, E, Dabrowska, M, Napora, P, Konieczny, M, Spyra, J, Lysek, R, Pijanowski, Z, Grzegorzewski, B, Bednarkiewicz, Z, Kinasz, L, Antkowiak-Piatyszek, K, Stania, K, Szpajer, M, Staneta, P, Skonieczny, G, Ksiezycka-Majczynska, E, Blicharski, T, Piepiorka, M, Wozakowska-Kaplon, B, Zechowicz, T, Ilkowski, J, Lubiszewska, B, Hiczkiewicz, J, Wierzbicka, K, Kosior, D, Garbocz, P, Kubica, J, Raczak, G, Wozniak, I, Cygler, J, Kramarczuk, E, Bystryk, L, Pentela-Nowicka, J, Dabrowski, M, Podolec, P, Zieba, B, Mosiewicz, J, Dubaniewicz, W, Banach, M, Tyszecka, G, Lepich, T, Rychlewska-Hanczewska, A, Guzik, T, Monteiro, P, Pereira, H, Oliveira, L, Matos, P, Soares Goncalves, S, Leitao, A, Vasco Salgado, A, Timoteo, At, Pintilei, E, Badila, E, Militaru, C, Tudoran, M, Arsenescu-Georgescu, C, Mitu, F, Zdrenghea, D, Lighezan, D, Teodorescu, I, Popescu, Mi, Coman, I, Vintila, Mm, Vishnevsky, A, Lukyanov, Y, Blokhin, A, Kostenko, V, Shvarts, Y, Markov, V, Motylev, I, Dronov, D, Sherenkov, A, Barbarash, O, Shutemova, E, Bolshakova, O, Kobalava, Z, Voevoda, M, Treshkur, T, Zrazhevskiy, K, Pimenov, L, Solovev, O, Tarasov, N, Arkhipov, M, Freidlin, M, Shalaev, S, Yakhontova, P, Shustov, S, Goloshchekin, B, Panov, A, Bart, B, Bubnova, M, Gordeev, I, Osipova, I, Tereshenko, S, Solovieva, E, Meshkov, A, Zateyshchikov, D, Tan, Jl, Subramaniam, T, Pella, D, Fulop, P, Antalik, L, Dzupina, A, Banikova, A, Sosovec, D, Urgeova, L, Mazur, J, Hranai, M, Banik, M, Vinanska, D, Lennerova, J, Kovar, F, Pastrnakova, E, Uhliar, R, Blasko, P, Gonsorcik, J, Lukacova, J, Oriesek, R, Hatalova, K, du Toit, M, Ebrahim, I, Vawda, G, Lipschitz, S, Blignaut, S, Engelbrecht, J, Coetzer, Tf, Pretorius, M, Urbach, D, Badat, A, Pillay, S, Van Zyl, L, Abelson, M, van der Walt, E, Moodley, R, Jacovides, A, Oosthuysen, Wm, Klug, E, Lottering, H, Kok, J, Saaiman, J, Dawood, S, De Jong DM, Kapp, C, Makotoko, E, Bayat, J, Sarvan, M, Vally, T, Stapelberg, A, Kim, M, Bae, J, Cho, Y, Kim, S, Han, Kh, Her, S, Kim, B, Lee, S, Hong, B, Kim, W, Rha, S, Jeong, M, Shin, Gj, Vida Gutierrez, M, Valdes Chavarri, M, Pinto Sala, X, Gonzalez Juanatey JR, Civeira Murillo, F, Zamorano Gomez JL, Lekuona Goya, I, Iñiguez Romo, A, Cordero Fort, A, Ascaso Gimilio JF, Millan Nuñez-Cortes, J, Lindholm, C, Söderberg, S, Suutari, A, Berglund, S, Mooe, T, Kusiak, D, Bandh, S, Dahlén, G, Olsson, S, Witt, N, Tydén, P, Johansson, P, Cizinsky, S, Falck, G, Pettersson, Si, Rasmanis, G, Östergren, J, Moccetti, T, Beer, Hj, Eberli, F, Krähenbühl, S, Linka, A, Ackermann, D, Michel, P, Yeh, H, Tsai, Cf, Wu, C, Hsia, C, Juang, J, Hsieh, I, Lai, W, Huang, C, Hsieh, Y, Sahin, T, Duzenli, M, Yigit, Z, Demir, M, Yilmaz, Mb, Muderrisoglu, Ih, Kirma, C, Ercan, E, Kayikcioglu, L, Balbay, Y, Lymar, I, Kulynych, O, Prokhorov, O, Karpenko, O, Kraіz, I, Vakaliuk, I, Stanislavchuk, M, Korzh, O, Rudyk, I, Zhurba, S, Svishchenko, Y, Tseluyko, V, Gyrina, O, Reshotko, D, Kopytsya, M, Volkov, V, Myshanych, G, Rebrov, B, Rishko, M, Rudenko, L, Shatylo, V, Parkhomenko, O, Yena, L, Golovchenko, O, Sorokina, I, Malynovsky, Y, Ivan, P, Blagden, M, Dear, H, Mathew, A, Lagocki, S, Kondagunta, V, Ahsan, A, Mckinnon, C, Douglas, F, Thom, S, Fiore, G, Caulfield, M, Lynch, M, Thomas, H, Bain, S, Hall, A, Mcnally, D, Fisher, M, Keeling, P, Al-Bahrani, A, Lip, G, Ellery, A, Purohit, J, Travill, C, Cappuccio, F, Davis, G, Gaunt, R, Adlam, D, Asamoah, N, Jaafar, F, Mccormack, T, Jupp, B, Pye, M, Ainsworth, P, Chauhan, A, Paul, N, Fairlie, H, Fox, C, Muzulu, S, Trevelyan, J, Aggarwal, R, Issa, B, Saravanan, P, Cruickshank, K, Gorog, D, Heller, S, Newby, D, Nicolson, A, Hare, Po, Donnelly, P, Rutherfurd, S, de Belder, M, Finlayson, J, Harvey, J, Hoye, A, Kingston, D, Sarkar, D, Negahban, A, Webster, J, Wyatt, N, Muir, S, Cummings, M, Mackenzie, I, Senior, R, Capps, N, Fotherby, K, Mcintyre, H, Aldegather, J, Dixon, L, Saksena, R, Butler, R, Ramstad, D, Pierpont, B, Levinson, D, Mohammed, A, Haddad, T, Goel, A, Dave, K, Haught, Wh, Desire, A, Hershon, K, Napoli, M, Tami, L, Rothschild, R, Khurana, S, Gupta, D, Cheung, D, Hearne, S, Grubb, S, Miller, A, Baird, I, Marcus, A, Srivastava, S, Forgosh, L, Fritz, R, Mays, M, Bertolet, B, Reddy, J, Khan, M, Nakhle, S, Dill, S, Fishbein, G, Khan, B, Marais, H, Reschak, M, Malone, M, Nadar, V, Whitney, R, Reichman, A, Reyes, H, El Shahawy, M, Rabinowitz, A, Weinstein, D, Farhat, N, Onyema, D, Potu, R, Runquist, L, Barnum, O, Crater, T, Fialkow, J, Shah, A, Thompson, C, Wiseman, A, Doyle, T, Henderson, D, Herzog, W, Schnitzler, R, Carr, K, Davis, M, Nagajothi, N, Olsen, S, Rogers, W, Rubino, J, Singh, I, Tarleton, G, Bhagwat, R, Clardy, D, Jardula, M, Robinson, J, Torres, M, Vijay, N, Farris, N, Lillo, J, Moriarty, P, Recknor, C, Berlacher, P, Christensen, T, Gabra, N, Issa, M, Janik, M, Lawless, A, Molter, D, Stout, E, Brezina, B, Claxton, E, Linsky, R, Poock, J, Remler, R, Roseman, H, Schramm, E, Al-Joundi, T, Amin, J, Hitchcock, J, Isserman, S, Kirstein, J, Rider, J, Shalek, M, Sherman, H, Bernstein, M, Chandra, L, Hatharasinghe, R, Ibrahim, H, Iteld, B, Linzmeyer, K, Seaton, B, Zeig, S, Christofides, E, Dunbar, R, Griffin, S, Kohli, N, Koren, M, Pharr, W, Purdy, D, Spencer, R, Yeoman, G, Banerjee, S, Cheek, Hb, Engel, E, Hamroff, G, Huling, R, Kozlowski, L, Levin, P, Makam, S, Meengs, M, Bhushan, R, Erickson, B, Herman, L, Lo, E, Mcdowell, E, Mcgrew, F, Miller, M, Ord, J, Webel, R, Wilhoit, G, Wise, J, Yang, E, Budoff, M, Collins, J, Dauber, I, Dobkin, L, Focil, A, Gandy, W, Pasquini, J, Ramos, M, Rodriguez, D, Rosenson, R, Sanford, K, Schlau, A, Snyder, B, Stonesifer, L, Tang, A, De Souza, J, Elam, M III, French, J, Guyton, J, Hage Korban, E, Kereiakes, D, King, M, Loh, I, Navarro, J, Simons, R, Tobin, T, Younis, L, Aboufakher, R, Baldari, D, Ballantyne, C, Broughton, R, Eaton, C, Johnston, J, Simon, W, Thomson, S, Vora, K, Youngman, D, Alzohaili, O, Auerbach, E, Brown, C, Burrough, B, Chen, Y, Gilpatrick, M, Landzberg, J, Mitchell, C, Rice, L, Rubenfire, M, Sofley, Cw, Strobl, D, Atassi, K, Davila, W, Diogo, J, Fagan, T, Joffe, I, Krishna, J, Osea, E, Penny, W, Rowe, W, Shapiro, M, Welker, J, Benton, R, Dobratz, D, Fortuin, F, Graham, J, Henry, B, Kusnick, B, Lutskiy, M, Mcrae, A, Saway, W, Scott, J, Shah, M, Weinberg, B, Zarich, S, Acheatel, R, Case, C, Earl, J, Fernandez, S, Giugliano, G, Handelsman, Y, Hermany, P, Holder, S, Kashyap, M, Khan, A, Lader, E, Peniston, J, Raoof, T, Sacco, J, Shore, K, Spriggs, D, Stringam, S, Tahirkheli, N, Delgado, E, Derian, W, Greenwald, J, Harris, M, Jackson, R, Marhefka, G, Mcelveen, W, Mooss, A, Morris, P, Murray, J, Pearlstein, P, Raisinghani, A, Rezkalla, S, Sakhrani, L, Schreibman, D, Shaoulian, E, Steinsapir, J, Yataco, A, De La Cruz, A, Fredrick, M, Goldenberg, E, Lee, D, Mccullum, K, Mclellan, B, Stephens, L, Wilson, S, Alfieri, A, Mandviwala, M, Orourke, D, Samal, A, Schmedtje, J, Waxman, F, Carhart, R, Clements, B, Dyke, C, Ghali, J, Gruberg, L, Hack, T, Jehle, A, Pogue, B, Schooley, C, Shifrin, G., National Institute for Health Research, Amgen Inc, University of Zurich, Sabatine, Marc S, Sabatine, M, Giugliano, R, Keech, A, Honarpour, N, Wiviott, S, Murphy, S, Kuder, J, Wang, H, Liu, T, Wasserman, S, Sever, P, Pedersen, T, Fish, M, Abrahamsen, T, Im, K, Kanevsky, E, Bonaca, M, Lira Pineda, A, Hanlon, K, Knusel, B, Somaratne, R, Kurtz, C, Scott, R, Accini Mendoza, J, Amerena, J, Badariene, J, Burgess, L, Ceska, R, Charng, M, Choi, D, Cobos, J, Dan, G, De Ferrari, G, Deedwania, P, Chopra, V, Erglis, A, Ezhov, M, Ferreira, J, Filipova, S, Gaciong, Z, Pasierski, T, Georgiev, B, Gonzalez-Galvez, G, Gouni-Berthold, I, Schaufele, T, Hirayama, A, Huber, K, Rammer, M, Kjaerulf Jensen, H, Wermuth, S, Jiang, L, Jukema, J, Kraydashenko, O, Leiter, L, Lewis, B, Lopez-Miranda, J, Lorenzatti, A, Mach, F, Mcadam, B, Nilsson, L, Olsson, A, Rallidis, L, Rogelio, G, Kerr Saraiva, J, Scheen, A, Schiele, F, Connolly, D, Siu, C, Tay, L, Thorgeirsson, G, Tikkanen, M, Tokgozoglu, S, Toth, K, Viigimaa, M, Wan Ahmad, W, Hennekens, C, Andreotti, F, Baigent, C, Brown, W, Davis, B, Newcomer, J, Wood, S, Larosa, J, Ansell, B, Lowe, C, Zahn, L, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, Singhal, A, Vita, J, Mackinnon, I, Vogel, D, Leon de la Fuente, R, Perna, E, Amuchastegui, M, Pacora, F, Hershson, A, Blumberg, E, Glenny, J, Colombo, H, Cuadrado, J, Nicolosi, L, Rojas, C, Ulla, M, Hasbani, E, Cuneo, C, Lopez Santi, R, Sanabria, H, Hrabar, A, Lozada, A, Begg, A, Lehman, S, Wittert, G, Juergens, C, Kostner, K, Beltrame, J, Simpson, R, Sinhal, A, Adams, M, Kritharides, L, Roberts Thomson, P, Cross, D, Thompson, P, Van Gaal, W, Cox, N, Farshid, A, Hammett, C, Garrahy, P, Prasan, A, Horrigan, M, Ebenbichler, C, Hanusch, U, Prager, R, Schernthaner, G, Luger, A, Siostrzonek, P, Toplak, H, Bergler-Klein, J, Paulweber, B, Sinzinger, H, Buysschaert, I, Thoeng, J, Vandekerckhove, H, Catez, E, Verheye, S, Descamps, O, Hoffer, E, Wollaert, B, Chenu, P, van de Borne, P, De Meulemeester, M, Friart, A, Charlier, F, De Raedt, H, Rietzschel, E, Roelandt, R, Lalmand, J, Tavares Russo, L, Reis, G, Duarte Barbosa, E, Vidotti, M, Fernandes Manenti, E, Dutra, O, Leaes, P, Rech, R, Bertolim Precoma, D, Nicolau, J, Amoedo, R, Eliaschewitz, F, Pereira, A, Kurtz Lisboa, H, Soares Piegas, L, Cunha Borges, J, Ferreira Rossi, P, Pimentel Filho, P, Bodanese, L, de Sa Cunha, R, Moura Jorge, J, Ardito, W, Barroso de Souza, W, Hissa, M, Izar, M, Manolova, A, Kitova, L, Kinova, E, Tzekova, M, Velchev, V, Tarnovska-Kadreva, R, Gotchev, D, Petrov, I, Raev, D, Trendafilova-Lazarova, D, Yotov, Y, Lazov, P, Rahimi, S, St Amour, E, Constance, C, Pesant, Y, Hess, A, Anderson, T, Sussex, B, Henein, S, Tsoukas, G, Pandey, A, Bergeron, J, Hart, R, Gosselin, G, Chehayeb, R, Hamet, P, Hartleib, M, Mukherjee, A, Halperin, F, Petrella, R, Bhargava, R, Lonn, E, Sabbah, E, Bata, I, Cha, J, Gaudet, D, Chapman, K, Murthy, D, Nigro, F, Rupka, D, Gossard, D, Gupta, M, Dowell, A, Mansour, S, Baass, A, Geadah, C, Huynh, T, Peterson, S, Poirier, P, Sabe-Affaki, G, Vertes, G, Crowley, D, Duchesne, L, Pincetti Jofre, C, Potthoff Cardenas, S, Conejeros Kindel, C, Saavedra Gajardo, V, Lanas Zanetti, F, Sepulveda Varela, P, Stockins Fernandez, B, Li, W, Li, D, Zhao, S, Li, Z, Wang, J, Yang, Y, Zhang, L, Yang, P, Zhang, X, Huang, H, Xue, L, Zheng, Z, Huang, W, Dai, H, Su, H, Zeng, X, Zheng, Y, Tang, Y, Yao, Z, Sun, Y, Du, Y, Ge, Z, Yan, J, Chen, X, Liu, F, Pei, H, Yang, X, Cui, H, Gu, Y, Yang, Z, Li, J, Lian, Y, Cui, Y, Wang, D, Jiang, J, Li, X, Chen, J, Mo, Z, Xu, P, He, Y, Zhou, C, Qu, P, Zhu, Y, Liu, Y, Shen, X, Gao, X, Terront Lozano, M, Moncada Corredor, M, Hernandez Triana, E, Botero Lopez, R, Coronel Arroyo, J, Quintero Baiz, A, Sanchez Vallejo, G, Arana Londono, C, Molina de Salazar, D, Castellanos Bueno, R, Manzur Jattin, F, Cure Cure, C, Sotomayor Herazo, A, Spinar, J, Hala, T, Machkova, M, Klimsa, Z, Polasek, R, Jerabek, O, Kazdera, P, Pozdisek, Z, Vaclavik, J, Frana, P, Elbl, L, Kucera, D, Kryza, R, Malecha, J, Reichert, P, Sochor, K, Ludka, O, Kellnerova, I, Peterka, K, Zidkova, E, Cech, V, Brabec, T, Fiserova, N, Kvasnicka, J, Rosolova, H, Nemecek, E, Adamkova, V, Dunaj, M, Pojsl, S, Cepelak, M, Podpera, I, Kuchar, L, Rysava, D, Burianova, H, Spinarova, L, Skrobakova, J, Charvat, J, Homza, M, Zemanek, J, Koleckar, P, Karen, I, Krupicka, J, Blaha, V, Matuska, J, Brotanek, J, Cifkova, R, Kuchar, R, Vomacka, Z, Kosek, Z, Hulinsky, V, Krejcova, H, Kuchar, J, Jelinek, Z, Jelinek, P, Markdanner Lindgren, L, Saetre Lihn, A, Korsgaard Thomsen, K, Bronnum-Schou, J, Nielsen, H, Nielsen, T, Egstrup, K, Klausen, I, Mickley, H, Hove, J, Jeppesen, J, Melchior, T, Schmidt, E, Valter, I, Rosenthal, A, Kaik, J, Kork, A, Alt, I, Strand, J, Nieminen, S, Kahri, J, Suomi, J, Nyman, K, Strandberg, T, Piippo, T, Savolainen, M, Vikman, S, Pucheu, Y, Cariou, B, Henry, P, Ferrari, E, Montalescot, G, Ferrieres, J, Roubille, F, Bonnet, B, Angoulvant, D, Range, G, Bammert, A, Delarche, N, Mariat, C, Cayla, G, Durlach, V, Coisne, D, Paillard, F, Rouzier, R, Goralski, M, Khanoyan, P, Cottin, Y, Ziegler, O, Khalife, K, Le Corvoisier, P, Motreff, P, Spaulding, C, Vanbelle, E, Bourhaial, H, Opitz, C, Kahrmann, G, Contzen, C, Appel, K, Schenkenberger, I, Rinke, A, Trenk, D, Maus, O, Karakas, M, Hanefeld, M, Darius, H, Hetzel, G, Munzel, T, Wohrle, J, Stawowy, P, Marten, I, Isermann, B, Kast, P, Vorpahl, M, Bosiljanoff, P, Hengstenberg, C, Kassner, U, Salbach, P, Fischer, M, Steiner, S, Wagner, S, Kraatz, U, von Hodenberg, E, Weyland, K, Mantas, I, Tziakas, D, Bousboulas, S, Patsilinakos, S, Mertzanos, G, Panagoulis, C, Bilianou, H, Skoumas, I, Elisaf, M, Manolis, A, Moschos, N, Kochiadakis, G, Ntaios, G, Richter, D, Athyros, V, Kolovou, G, Danias, P, Melidonis, A, Fan, K, Siu, S, Hornyik, A, Lakatos, F, Zilahi, Z, Nagy, K, Laszlo, Z, Peterfai, E, Lupkovics, G, Andreka, P, Merkely, B, Herczeg, B, Piros, G, Salamon, C, Mark, L, Papp, A, Szakal, I, Edes, I, Mohacsi, A, Tomcsanyi, J, Hajko, E, Nagy, A, Papp, E, Kiss, R, Karadi, I, Sigurdsson, A, Jain, A, Pai, R, Kothiwale, V, Kulkarni, G, Mahajan, A, Aggarwal, S, Mehta, V, Rajadhyaksha, G, Joshi, A, Khandait, V, Parmar, M, Tyagi, S, Airody Govinda, R, Dwivedi, S, Parikh, K, Pothineni, R, Solanki, B, O'Donnell, M, Crean, P, Barton, J, Shechter, M, Shotan, A, Klutstein, M, Chorin, E, Gavish, D, Kracoff, O, Atar, S, Rigler, S, Hasin, Y, Schiff, E, Merlini, P, Rapezzi, C, Pirro, M, Gonnelli, S, Floresta, A, Mennuni, M, Ardissino, D, Senni, M, Marenzi, G, Marcucci, R, Sampietro, T, Cosmi, F, Perrone Filardi, P, De Caterina, R, Fedele, F, Moretti, L, Biasucci, L, Ferri, C, Go, Y, Kiyosue, A, Higashi, Y, Tokunaga, T, Kawasaki, T, Sakagami, S, Namba, S, Saku, K, Oku, K, Arakawa, T, Iida, H, Nakamura, Y, Yamamoto, K, Hata, Y, Katsuda, Y, Koga, Y, Shimizu, M, Uehara, H, Kajiyama, S, Okamoto, H, Shinozaki, T, Fujino, Y, Funazaki, T, Higa, N, Kaigawa, K, Koike, A, Nakane, H, Sato, K, Satoh, Y, Shirasawa, K, Sugino, H, Tanabe, J, Uemura, O, Yoshimichi, G, Akai, A, Himeno, H, Inage, T, Inoko, M, Kadokami, T, Noguchi, Y, Yamashita, K, Yasumura, Y, Yuge, M, Hosokawa, S, Kawamitsu, K, Kozuma, K, Matsuo, H, Nakashima, E, Okada, M, Wada, A, Yokoya, K, Iwade, K, Kawabata, K, Tanno, H, Ako, J, Fujita, H, Izumiya, Y, Kanno, M, Nunohiro, T, Ohmura, H, Ueno, T, Kakurina, N, Jasinkevica, I, Stukena, I, Veze, I, Eglite, R, Teterovska, D, Sime, I, Strazdiene, V, Venceviciene, L, Gustiene, O, Radzeviciene-Jurgute, R, Kucinskiene, A, Maskon, O, Lee, C, Erng, T, Gan, H, Mohamed Yusof, A, Ramanathan, G, Liew, H, Lopez Alvarado, A, Nevarez Ruiz, L, De los Rios Ibarra, M, Bazzoni Ruiz, A, Ramos Lopez, G, Llamas Esperon, G, De la Pena Topete, G, Violante Ortiz, R, Illescas Diaz, J, Leon Gonzalez, S, Sanchez Diaz, C, Mendez Machado, G, Venegas Carrillo, L, Aldrete Velasco, J, Cardona Munoz, E, Leiva Pons, J, Perez Alva, J, van der Zwaan, C, Oomen, A, van de Wal, R, Magro, M, Boswijk, D, Janus, C, Groutars, R, Tonino, W, Cornel, J, Oude Ophuis, A, Troquay, R, Liem, A, Westendorp, I, Van Hessen, M, Lok, D, De Nooijer, C, Den Hartog, F, Van Beek, E, Bendermacher, P, Jansen, R, Romer, T, Rensing, B, Hersbach, F, Herrman, J, Ladyjanskaia, G, Karalis, I, Linssen, G, Bokern, M, Visman, A, Kooij, A, Monajemi, H, Lieverse, A, Baker, J, Tie, S, Risberg, K, Hysing, J, Hoivik, H, Norheim, P, Solnor, L, Hovland, A, Kjaernli, T, Jocson, G, Coching, R, Batalla, E, Go, A, Habaluyas, R, Barcinas, R, Sy, R, Estepar, R, Germar, A, Trebacz, J, Szymkowiak, K, Wnetrzak-Michalska, R, Kopaczewski, J, Przekwas-Jaruchowska, M, Kania, G, Zabowka, M, Mirek-Bryniarska, E, Dabrowska, M, Napora, P, Konieczny, M, Spyra, J, Lysek, R, Pijanowski, Z, Grzegorzewski, B, Bednarkiewicz, Z, Kinasz, L, Antkowiak-Piatyszek, K, Stania, K, Szpajer, M, Staneta, P, Skonieczny, G, Ksiezycka-Majczynska, E, Blicharski, T, Piepiorka, M, Wozakowska-Kaplon, B, Zechowicz, T, Ilkowski, J, Lubiszewska, B, Hiczkiewicz, J, Wierzbicka, K, Kosior, D, Garbocz, P, Kubica, J, Raczak, G, Wozniak, I, Cygler, J, Kramarczuk, E, Bystryk, L, Pentela-Nowicka, J, Dabrowski, M, Podolec, P, Zieba, B, Mosiewicz, J, Dubaniewicz, W, Banach, M, Tyszecka, G, Lepich, T, Rychlewska-Hanczewska, A, Guzik, T, Monteiro, P, Pereira, H, Oliveira, L, Matos, P, Soares Goncalves, S, Leitao, A, Vasco Salgado, A, Timoteo, A, Pintilei, E, Badila, E, Militaru, C, Tudoran, M, Arsenescu-Georgescu, C, Mitu, F, Zdrenghea, D, Lighezan, D, Teodorescu, I, Popescu, M, Coman, I, Vintila, M, Vishnevsky, A, Lukyanov, Y, Blokhin, A, Kostenko, V, Shvarts, Y, Markov, V, Motylev, I, Dronov, D, Sherenkov, A, Barbarash, O, Shutemova, E, Bolshakova, O, Kobalava, Z, Voevoda, M, Treshkur, T, Zrazhevskiy, K, Pimenov, L, Solovev, O, Tarasov, N, Arkhipov, M, Freidlin, M, Shalaev, S, Yakhontova, P, Shustov, S, Goloshchekin, B, Panov, A, Bart, B, Bubnova, M, Gordeev, I, Osipova, I, Tereshenko, S, Solovieva, E, Meshkov, A, Zateyshchikov, D, Tan, J, Subramaniam, T, Pella, D, Fulop, P, Antalik, L, Dzupina, A, Banikova, A, Sosovec, D, Urgeova, L, Mazur, J, Hranai, M, Banik, M, Vinanska, D, Lennerova, J, Kovar, F, Pastrnakova, E, Uhliar, R, Blasko, P, Gonsorcik, J, Lukacova, J, Oriesek, R, Hatalova, K, du Toit, M, Ebrahim, I, Vawda, G, Lipschitz, S, Blignaut, S, Engelbrecht, J, Coetzer, T, Pretorius, M, Urbach, D, Badat, A, Pillay, S, Van Zyl, L, Abelson, M, van der Walt, E, Moodley, R, Jacovides, A, Oosthuysen, W, Klug, E, Lottering, H, Kok, J, Saaiman, J, Dawood, S, De Jong, D, Kapp, C, Makotoko, E, Bayat, J, Sarvan, M, Vally, T, Stapelberg, A, Kim, M, Bae, J, Cho, Y, Kim, S, Han, K, Her, S, Kim, B, Lee, S, Hong, B, Kim, W, Rha, S, Jeong, M, Shin, G, Vida Gutierrez, M, Valdes Chavarri, M, Pinto Sala, X, Gonzalez Juanatey, J, Civeira Murillo, F, Zamorano Gomez, J, Lekuona Goya, I, Iniguez Romo, A, Cordero Fort, A, Ascaso Gimilio, J, Millan Nunez-Cortes, J, Lindholm, C, Soderberg, S, Suutari, A, Berglund, S, Mooe, T, Kusiak, D, Bandh, S, Dahlen, G, Olsson, S, Witt, N, Tyden, P, Johansson, P, Cizinsky, S, Falck, G, Pettersson, S, Rasmanis, G, Ostergren, J, Moccetti, T, Beer, H, Eberli, F, Krahenbuhl, S, Linka, A, Ackermann, D, Michel, P, Yeh, H, Tsai, C, Wu, C, Hsia, C, Juang, J, Hsieh, I, Lai, W, Huang, C, Hsieh, Y, Sahin, T, Duzenli, M, Yigit, Z, Demir, M, Yilmaz, M, Muderrisoglu, I, Kirma, C, Ercan, E, Kayikcioglu, L, Balbay, Y, Lymar, I, Kulynych, O, Prokhorov, O, Karpenko, O, Kraіz, I, Vakaliuk, I, Stanislavchuk, M, Korzh, O, Rudyk, I, Zhurba, S, Svishchenko, Y, Tseluyko, V, Gyrina, O, Reshotko, D, Kopytsya, M, Volkov, V, Myshanych, G, Rebrov, B, Rishko, M, Rudenko, L, Shatylo, V, Parkhomenko, O, Yena, L, Golovchenko, O, Sorokina, I, Malynovsky, Y, Ivan, P, Blagden, M, Dear, H, Mathew, A, Lagocki, S, Kondagunta, V, Ahsan, A, Mckinnon, C, Douglas, F, Thom, S, Fiore, G, Caulfield, M, Lynch, M, Thomas, H, Bain, S, Hall, A, Mcnally, D, Fisher, M, Keeling, P, Al-Bahrani, A, Lip, G, Ellery, A, Purohit, J, Travill, C, Cappuccio, F, Davis, G, Gaunt, R, Adlam, D, Asamoah, N, Jaafar, F, Mccormack, T, Jupp, B, Pye, M, Ainsworth, P, Chauhan, A, Paul, N, Fairlie, H, Fox, C, Muzulu, S, Trevelyan, J, Aggarwal, R, Issa, B, Saravanan, P, Cruickshank, K, Gorog, D, Heller, S, Newby, D, Nicolson, A, Hare, P, Donnelly, P, Rutherfurd, S, de Belder, M, Finlayson, J, Harvey, J, Hoye, A, Kingston, D, Sarkar, D, Negahban, A, Webster, J, Wyatt, N, Muir, S, Cummings, M, Mackenzie, I, Senior, R, Capps, N, Fotherby, K, Mcintyre, H, Aldegather, J, Dixon, L, Saksena, R, Butler, R, Ramstad, D, Pierpont, B, Levinson, D, Mohammed, A, Haddad, T, Goel, A, Dave, K, Haught, W, Desire, A, Hershon, K, Napoli, M, Tami, L, Rothschild, R, Khurana, S, Gupta, D, Cheung, D, Hearne, S, Grubb, S, Miller, A, Baird, I, Marcus, A, Srivastava, S, Forgosh, L, Fritz, R, Mays, M, Bertolet, B, Reddy, J, Khan, M, Nakhle, S, Dill, S, Fishbein, G, Khan, B, Marais, H, Reschak, M, Malone, M, Nadar, V, Whitney, R, Reichman, A, Reyes, H, El Shahawy, M, Rabinowitz, A, Weinstein, D, Farhat, N, Onyema, D, Potu, R, Runquist, L, Barnum, O, Crater, T, Fialkow, J, Shah, A, Thompson, C, Wiseman, A, Doyle, T, Henderson, D, Herzog, W, Schnitzler, R, Carr, K, Davis, M, Nagajothi, N, Olsen, S, Rogers, W, Rubino, J, Singh, I, Tarleton, G, Bhagwat, R, Clardy, D, Jardula, M, Robinson, J, Torres, M, Vijay, N, Farris, N, Lillo, J, Moriarty, P, Recknor, C, Berlacher, P, Christensen, T, Gabra, N, Issa, M, Janik, M, Lawless, A, Molter, D, Stout, E, Brezina, B, Claxton, E, Linsky, R, Poock, J, Remler, R, Roseman, H, Schramm, E, Al-Joundi, T, Amin, J, Hitchcock, J, Isserman, S, Kirstein, J, Rider, J, Shalek, M, Sherman, H, Bernstein, M, Chandra, L, Hatharasinghe, R, Ibrahim, H, Iteld, B, Linzmeyer, K, Seaton, B, Zeig, S, Christofides, E, Dunbar, R, Griffin, S, Kohli, N, Koren, M, Pharr, W, Purdy, D, Spencer, R, Yeoman, G, Banerjee, S, Cheek, H, Engel, E, Hamroff, G, Huling, R, Kozlowski, L, Levin, P, Makam, S, Meengs, M, Bhushan, R, Erickson, B, Herman, L, Lo, E, Mcdowell, E, Mcgrew, F, Miller, M, Ord, J, Webel, R, Wilhoit, G, Wise, J, Yang, E, Budoff, M, Collins, J, Dauber, I, Dobkin, L, Focil, A, Gandy, W, Pasquini, J, Ramos, M, Rodriguez, D, Rosenson, R, Sanford, K, Schlau, A, Snyder, B, Stonesifer, L, Tang, A, De Souza, J, Elam, M, French, J, Guyton, J, Hage Korban, E, Kereiakes, D, King, M, Loh, I, Navarro, J, Simons, R, Tobin, T, Younis, L, Aboufakher, R, Baldari, D, Ballantyne, C, Broughton, R, Eaton, C, Johnston, J, Simon, W, Thomson, S, Vora, K, Youngman, D, Alzohaili, O, Auerbach, E, Brown, C, Burrough, B, Chen, Y, Gilpatrick, M, Landzberg, J, Mitchell, C, Rice, L, Rubenfire, M, Sofley, C, Strobl, D, Atassi, K, Davila, W, Diogo, J, Fagan, T, Joffe, I, Krishna, J, Osea, E, Penny, W, Rowe, W, Shapiro, M, Welker, J, Benton, R, Dobratz, D, Fortuin, F, Graham, J, Henry, B, Kusnick, B, Lutskiy, M, Mcrae, A, Saway, W, Scott, J, Shah, M, Weinberg, B, Zarich, S, Acheatel, R, Case, C, Earl, J, Fernandez, S, Giugliano, G, Handelsman, Y, Hermany, P, Holder, S, Kashyap, M, Khan, A, Lader, E, Peniston, J, Raoof, T, Sacco, J, Shore, K, Spriggs, D, Stringam, S, Tahirkheli, N, Delgado, E, Derian, W, Greenwald, J, Harris, M, Jackson, R, Marhefka, G, Mcelveen, W, Mooss, A, Morris, P, Murray, J, Pearlstein, P, Raisinghani, A, Rezkalla, S, Sakhrani, L, Schreibman, D, Shaoulian, E, Steinsapir, J, Yataco, A, De La Cruz, A, Fredrick, M, Goldenberg, E, Lee, D, Mccullum, K, Mclellan, B, Stephens, L, Wilson, S, Alfieri, A, Mandviwala, M, Orourke, D, Samal, A, Schmedtje, J, Waxman, F, Carhart, R, Clements, B, Dyke, C, Ghali, J, Gruberg, L, Hack, T, Jehle, A, Pogue, B, Schooley, C, and Shifrin, G
- Subjects
Male ,STATIN THERAPY ,2700 General Medicine ,Disease ,Cardiovascular ,PLACEBO-CONTROLLED TRIAL ,Gastroenterology ,0302 clinical medicine ,Anticholesteremic Agent ,Medicine ,Myocardial infarction ,11 Medical and Health Sciences ,ddc:616 ,Incidence ,Antibodies, Monoclonal ,General Medicine ,Cholesterol ,Cardiovascular Diseases ,Monoclonal ,Drug Therapy, Combination ,Proprotein Convertase 9 ,Antibody ,Aged ,Anticholesteremic Agents ,Atherosclerosis ,Cholesterol, LDL ,Double-Blind Method ,Female ,Follow-Up Studies ,Humans ,Hydroxymethylglutaryl-CoA Reductase Inhibitors ,Hypercholesterolemia ,Least-Squares Analysis ,Middle Aged ,Medicine (all) ,REDUCING LIPIDS ,Human ,medicine.medical_specialty ,Evinacumab ,Clinical Trials and Supportive Activities ,PCSK9 INHIBITION ,Follow-Up Studie ,LDL ,03 medical and health sciences ,Drug Therapy ,Clinical Research ,LDL-C ,Least-Squares Analysi ,Science & Technology ,Unstable angina ,PCSK9 ,medicine.disease ,chemistry ,Clinical Biochemistry ,030204 cardiovascular system & hematology ,Bococizumab ,FOURIER Steering Committee and Investigators ,Medical and Health Sciences ,chemistry.chemical_compound ,Antibodies monoclonal ,Cardiovascular Disease ,030212 general & internal medicine ,Stroke ,Humanized ,RISK ,biology ,PCSK9 Inhibitors ,10051 Rheumatology Clinic and Institute of Physical Medicine ,Heart Disease ,Atherosclerosi ,6.1 Pharmaceuticals ,Combination ,Cardiology ,Life Sciences & Biomedicine ,Antibodies, Monoclonal, Humanized ,EZETIMIBE ,610 Medicine & health ,Antibodies ,Medicine, General & Internal ,General & Internal Medicine ,Internal medicine ,CORONARY-HEART-DISEASE ,In patient ,Heart Disease - Coronary Heart Disease ,Alirocumab ,Ldl cholesterol ,business.industry ,Evaluation of treatments and therapeutic interventions ,Evolocumab ,Good Health and Well Being ,Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE ,biology.protein ,MODERATE ,Hydroxymethylglutaryl-CoA Reductase Inhibitor ,business - Abstract
Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. Methods We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. Results At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P
- Published
- 2017
18. Cholesterol management in women and the elderly
- Author
-
LAROSA, J. C.
- Published
- 1997
19. Evolocumab and clinical outcomes in patients with cardiovascular disease
- Author
-
Sabatine, MS, Giugliano, RP, Keech, AC, Honarpour, N, Wiviott, SD, Murphy, SA, Kuder, JF, Wang, H, Liu, T, Wasserman, SM, Sever, PS, Pedersen, TR, Fish, MP, Abrahamsen, TE, Im, K, Kanevsky, E, Bonaca, MP, Lira Pineda, A, Hanlon, K, Knusel, B, Somaratne, R, Kurtz, C, Scott, R, Accini Mendoza, JL, Amerena, J, Badariene, J, Burgess, L, Ceska, R, Charng, MJ, Choi, D, Cobos, JL, Dan, GA, De Ferrari, GM, Deedwania, PC, Chopra, VK, Erglis, A, Ezhov, MV, Ferreira, J, Filipová, S, Gaciong, ZA, Pasierski, T, Georgiev, BG, Gonzalez-Galvez, G, Gouni-Berthold, I, Schäufele, T, Hirayama, A, Huber, K, Rammer, M, Kjaerulf Jensen, H, Wermuth, S, Jiang, L, Jukema, JW, Kraydashenko, O, Leiter, LA, Lewis, BS, López-Miranda, J, Lorenzatti, AJ, Mach, F, McAdam, B, Nilsson, L, Olsson, A, Rallidis, L, Rogelio, GG, Kerr Saraiva, JF, Scheen, A, Schiele, F, Connolly, D, Siu, CW, Tay, L, Thorgeirsson, G, Tikkanen, MJ, Tokgozoglu, SL, Toth, K, Viigimaa, M, Wan Ahmad, WA, Hennekens, CH, Andreotti, F, Baigent, C, Brown, WV, Davis, BR, Newcomer, JW, Wood, SK, LaRosa, J, Ansell, B, Lowe, C, Zahn, L, Awtry, E, Berger, C, Croce, K, Desai, A, Gelfand, E, Ho, C, Leeman, D, Link, M, Norden, A, Pande, A, Rost, N, Ruberg, F, Silverman, S, and Singhal, A
- Abstract
© 2017 Massachusetts Medical Society. BACKGROUND Evolocumab is a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels by approximately 60%. Whether it prevents cardiovascular events is uncertain. METHODS We conducted a randomized, double-blind, placebo-controlled trial involving 27,564 patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or higher who were receiving statin therapy. Patients were randomly assigned to receive evolocumab (either 140 mg every 2 weeks or 420 mg monthly) or matching placebo as subcutaneous injections. The primary efficacy end point was the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization. The key secondary efficacy end point was the composite of cardiovascular death, myocardial infarction, or stroke. The median duration of follow-up was 2.2 years. RESULTS At 48 weeks, the least-squares mean percentage reduction in LDL cholesterol levels with evolocumab, as compared with placebo, was 59%, from a median baseline value of 92 mg per deciliter (2.4 mmol per liter) to 30 mg per deciliter (0.78 mmol per liter) (P
- Published
- 2017
20. The value of commercial funding in health services research: the case of the APACHE III methodology
- Author
-
Knaus, W A, LaRosa, J C, Marks, R D, and Bisbee, G E
- Subjects
Research Support as Topic ,Commerce ,Humans ,Health Services Research ,Severity of Illness Index ,Software ,United States ,Research Article ,Capital Financing ,Information Systems - Published
- 1994
21. Cholestyramine in Type II Hyperlipoproteinemia: A Double-Blind Trial
- Author
-
LEVY, R. I., FREDRICKSON, D. S., STONE, N. J., BILHEIMER, D. W., BROWN, W. V., GLUECK, C. J., GOTTO, A. M., HERBERT, P. N., KWITEROVICH, P. O., LANGER, T., LaROSA, J., LUX, S. E., RIDER, A. K., SHULMAN, R. S., and SLOAN, H. R.
- Published
- 1973
22. Seasonal particulate carbon flux in the coastal northwestern mediterranean-sea, and the role of zooplankton fecal matter
- Author
-
Fowler, Sw, Small, Lf, and Larosa, J
- Subjects
PARTICULATE CARBON FLUX ,SEASONAL PARTICLES FLUX ,SEDIMENT TRAPS ,FECAL PELLETS - Abstract
During a six-year (1978-1984) sediment trap study in the northwestern Mediterranean off the coast of Monaco, large variations in mass flux and carbon flux through 100 and 150 m were observed with maximum flux values occurring in late winter or early spring and minimum flux in late summer. Total particulate carbon flux was linearly related to mass flux. During March through October total particulate carbon flux represented, on average, approximately 7 % of the mass flux, whereas from November through February it averaged about 4.7 %. From recent organic carbon content data collected in the same region, it was estimated that approximately 5 % of the total mass flux through 100 and 150 m in calm seas was organic carbon (calm seas were prevalent during March through October). Organic carbon export out of the euphotic zone ("new production") ranged from 17 to 42 % of primary production. Zooplankton fecal pellets were always an abundant component of the sinking particles and the pellet carbon flux was linearly related to the total carbon flux at the three depths (50, 150 and 250 m) examined. Higher pellet fluxes were always observed at the greater depths. Pellet carbon fluxes were calculated to be roughly 25, 29 and 33 % of total particulate carbon fluxes through 50, 150 and 250 m, respectively. These estimates suggested that zooplankton fecal pellet deposition is a significant contributor to the downward particulate carbon flux in this region of the northwestern Mediterranean Sea.
- Published
- 1991
23. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
- Author
-
Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart J, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, and Waters D
- Abstract
OBJECTIVE: The Treating to New Targets study showed that intensive lipid-lowering therapy with atorvastatin 80 mg/day provides significant clinical benefit beyond that afforded by atorvastatin 10 mg/day in patients with stable coronary heart disease (CHD). The objective of our study was to investigate whether similar benefits of high-dose intensive atorvastatin therapy can be achieved in patients with CHD and diabetes. RESEARCH DESIGN AND METHODS: A total of 1,501 patients with diabetes and CHD, with LDL cholesterol levels of <130 mg/dl, were randomized to double-blind therapy with either atorvastatin 10 (n = 753) or 80 (n = 748) mg/day. Patients were followed for a median of 4.9 years. The primary end point was the time to first major cardiovascular event, defined as death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitated cardiac arrest, or fatal or nonfatal stroke. RESULTS: End-of-treatment mean LDL cholesterol levels were 98.6 mg/dl with atorvastatin 10 mg and 77.0 mg/dl with atorvastatin 80 mg. A primary event occurred in 135 patients (17.9%) receiving atorvastatin 10 mg, compared with 103 patients (13.8%) receiving atorvastatin 80 mg (hazard ratio 0.75 [95% CI 0.58-0.97], P = 0.026). Significant differences between the groups in favor of atorvastatin 80 mg were also observed for time to cerebrovascular event (0.69 [0.48-0.98], P = 0.037) and any cardiovascular event (0.85 [0.73-1.00], P = 0.044). There were no significant differences between the treatment groups in the rates of treatment-related adverse events and persistent elevations in liver enzymes. CONCLUSIONS: Among patients with clinically evident CHD and diabetes, intensive therapy with atorvastatin 80 mg significantly reduced the rate of major cardiovascular events by 25% compared with atorvastatin 10 mg. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
24. Prevention and treatment of coronary heart disease: who benefits?
- Author
-
LaRosa JC and LaRosa, J C
- Published
- 2001
25. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials.
- Author
-
LaRosa JC, He J, Vupputuri S, LaRosa, J C, He, J, and Vupputuri, S
- Abstract
Context: Lowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women.Objective: To estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women.Data Sources: Trials published in English-language journals were retrieved by searching MEDLINE (1966-December 1998), bibliographies, and authors' reference files.Study Selection: Studies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified).Data Extraction: Information on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus.Data Synthesis: Data from the 5 trials, with 30 817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Stati n drug treatment was associated with a20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol. Overall, statin drug treatment reduced risk 31 % in major coronary events (95% confidence interval [CI], 26%-36%) and 21 % in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%; 95% Cl, 13 %-42 %) and men (31 %; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31 %; 95% CI, 24%-36%).Conclusions: Our meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
26. Androgens and women's health: genetic and epidemiologic aspects of lipid metabolism.
- Author
-
LaRosa, J C
- Abstract
Lipoprotein metabolism may be viewed as a process whereby large, triglyceride-carrying particles from the intestine and liver are broken down into smaller cholesterol-enriched lipoprotein particles. In the process, triglyceride is transported from the intestine and liver to adipose and other storage tissues. Androgen appears to affect lipoprotein metabolism in a number of ways. These include: increasing the activity of lipoprotein lipase and hepatic triglyceride lipase, resulting in higher levels of triglyceride in adipose tissue and a drop in total circulating high-density lipoprotein levels, respectively, and decreasing catabolic removal of low-density lipoproteins from circulating plasma. In pre- and postmenopausal women, androgen progestins in some oral contraceptives, especially the older 19-nortestosterone derivatives such as norgestrel, lower high-density lipoprotein and raise low-density lipoprotein levels. Newer 19-nortestosterone derivatives, such as desogestrel and norgestimate, have a lesser effect on circulating lipoproteins. Nonoral androgenic progestins (e.g., subcutaneous norgestrel) have little effect on circulating lipids, however, which indicates the significance of the "first pass" through the liver for oral agents. The effects of androgens on atherogenesis are largely unexplored, although preliminary studies indicate that they may promote the atherogenic process. [ABSTRACT FROM AUTHOR]
- Published
- 1995
- Full Text
- View/download PDF
27. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
- Author
-
LaRosa, J C, Sneider, G B, and Boyle, C
- Subjects
- *
CLINICAL drug trials -- Law & legislation , *ANTILIPEMIC agents , *ARTERIOSCLEROSIS , *CLINICAL trials , *CORONARY disease , *CLINICAL drug trials , *LIPIDS , *SAFETY - Published
- 1998
28. Chronic acalculous gallbladder disease: a clinical variant.
- Author
-
Frykberg, E R, Duong, T C, LaRosa, J J, and Etienne, H B
- Published
- 1988
- Full Text
- View/download PDF
29. Combined procedure for the determination of90Sr,241Am and Pu radionuclides in soil samples.
- Author
-
Moreno, J., Vajda, N., Danesi, P., Larosa, J., Zeiller, E., and Sinojmeri, M.
- Abstract
A combined procedure for sequential determination of low level activity concentrations of
90 Sr,241 Am and Pu radionuclides is described. The analysis of α-emitters is performed by isotope dilution α-spectrometry using242 Pu or236 Pu and243 Am tracers. Strontium-90 is analyzed by liquid scintillation counting using the double energetic windows method. The method combines the well established, procedure for Pu analysis based on anion exchange, the powerful and selective method for Sr isolation based on extraction chromatography using Sr-Spec resin and finally it includes the application of the TRU-Spec column for separation and purification of the Am fraction. The radiochemical procedure was tested using IAEA reference and intercomparison materials. Major parameters of the procedure as well as advantages and drawbacks are discussed in detail. [ABSTRACT FROM AUTHOR]- Published
- 1997
- Full Text
- View/download PDF
30. Lipids in postmenopausal women: baseline findings of the Postmenopausal Estrogen/Progestin Interventions Trial.
- Author
-
Schrott HG, Legault C, Stefanick ML, Miller VT, Larosa J, Wood PD, and Lippel K
- Published
- 1994
- Full Text
- View/download PDF
31. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I.
- Author
-
Miller, Valery T., Muesing, Richard A., Larosa, John C., Stoy, Diane B., Phillips, Elizabeth A., Stillman, Robert J., Miller, V T, Muesing, R A, LaRosa, J C, Stoy, D B, Phillips, E A, and Stillman, R J
- Published
- 1991
32. Abstract: 26 HIGH-DOSE ATORVASTATIN PROVIDES SUSTAINED BENEFIT IN REDUCING RISK OF CV DISEASE AMONG STABLE CHD PATIENTS ≥65 YEARS
- Author
-
Wenger, N, LaRosa, J, and Shepherd, J
- Published
- 2009
- Full Text
- View/download PDF
33. EFFECT OF INTENSIVE CHOLESTEROL LOWERING WITH ATORVASTATIN 80MG IN PATIENTS WITH PREVIOUS REVASCULARIZATION: A TREATING TO NEW TARGETS (TNT) SUBSTUDY
- Author
-
Waters, D., Johnson, C., Bittner, V., DeMicco, D., Breazna, A., and LaRosa, J.
- Published
- 2008
- Full Text
- View/download PDF
34. Pleiotropic effects of statins and their clinical significance.
- Author
-
LaRosa, John C. and LaRosa, J C
- Subjects
- *
HEART diseases , *CARDIOLOGY - Abstract
Studies the significance of the pleiotropic effects of statins. Effect of statins on the elements of the thrombotic process; Absence of a consistent pattern that would allow differentiation of one statin from another on the basis of the pleiotropic effects; Possibility that the nonlipid effects of statins may not be limited to attenuation of atherogenesis.
- Published
- 2001
- Full Text
- View/download PDF
35. Physical activity and coronary heart disease among asymptomatic hypercholesterolemic men (the Lipid Research Clinics Coronary Primary Prevention Trial)
- Author
-
Johnson, J L, LaRosa, J C, Hyde, J S, Siscovick, D S, Ekelund, L G, and Gordon, D J
- Abstract
We examined the relation between reported regular strenuous exercise or hard physical labor and the incidence of coronary heart disease (CHD) death and nonfatal myocardial infarction among 1,533 hypercholesterolemic men aged 35-39 years who were in the placebo group of the Lipid Research Clinics Coronary Primary Prevention Trial. The mean follow-up of the cohort was 7.4 years. The men were free of clinical heart disease at entry; men with an abnormal resting electrocardiogram or graded exercise test also were excluded. Regular physical activity was not associated with the incidence of CHD (RR = .94, 95% CI = .68, 1.38) in this study population. Adjustment by the proportional hazards model for age, low-density lipoprotein cholesterol, smoking, family history of CHD, and occupation did not alter this finding. This observation suggests that reported regular physical activity may not be related to the risk of coronary heart disease among asymptomatic, hypercholesterolemic, middle-aged men.
- Published
- 1988
- Full Text
- View/download PDF
36. Issues and answers: curreNt challenges of treatment.
- Author
-
LaRosa, J. C.
- Published
- 1992
- Full Text
- View/download PDF
37. Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease.
- Author
-
Waters, D. D., LaRosa, J. C., and Barter, P.
- Subjects
- *
CORONARY disease , *CEREBROVASCULAR disease , *THERAPEUTICS , *CARDIOLOGY - Abstract
The article presents the abstract of the study "Atorvastatin at 80 mg/day reduced cerebrovascular events more than atorvastatin at 10 mg/day in stable coronary heart disease." It features the results that cerebrovascular events and strokes were lower in the 80 milligrams than in 10 milligram. It also highlights the conclusion that intensive atorvastatin therapy was more effective than moderate atorvastatin therapy in patient with stable coronary heart disease.
- Published
- 2007
38. Comparative study of plutonium and Americium bioaccumulation from two marine sediments contaminated in the natural environment
- Author
-
Hamilton, T.F., Fowler, S.W., LaRosa, J., Holm, E., Smith, J.D., Aarkrog, A., and Dahlgaard, H.
- Published
- 1991
- Full Text
- View/download PDF
39. A novel technique for the simultaneous determination of 210Pb and 210Po using a crown ether
- Author
-
Vajda, N., LaRosa, J., Zeisler, R., Danesi, P., and Kis-Benedek, Gy.
- Published
- 1997
- Full Text
- View/download PDF
40. Effect of Different Radiotracer Labelling Techniques on RadionuclideExcretion from Marine Organisms
- Author
-
LaRosa, J., Fowler, S. W., Renfro, W. C., and Heyraud, M.
- Subjects
EXCRETORY organs ,MARINE biology ,RADIATION ,RADIOISOTOPES - Published
- 1975
41. Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults.
- Author
-
Hoerger TJ, Bala MV, Bray JW, Wilcosky TC, LaRosa J, Hoerger, T J, Bala, M V, Bray, J W, Wilcosky, T C, and LaRosa, J
- Abstract
To estimate the fraction of United States (U.S.) adults who are eligible for treatment to reduce elevated low-density lipoprotein (LDL) cholesterol levels based on Adult Treatment Panel II (ATP II) guidelines and the percent reduction in LDL cholesterol required by those who qualify for treatment, we analyzed data on 7,423 respondents to Phase 2 of the third National Health and Nutrition Examination Survey (NHANES III) administered between 1991 and 1994. Approximately 28% of the U.S. adult population aged > or = 20 years is eligible for treatment based on ATP II guidelines. Eighty-two percent of adults with coronary heart disease are not at their target LDL cholesterol level of 100 mg/dl. Of those eligible for treatment, 65% report that they receive no treatment. Overall, 40% of people who qualify for drug therapy require an LDL cholesterol reduction of > 30% to meet their ATP II treatment goal. Approximately 75% of those with coronary heart disease who qualify for drug therapy require an LDL cholesterol reduction of >30%. Although elevated LDL cholesterol levels can be treated, prevalence rates in the U.S. adult population remain high. Several recent studies indicate that a considerable percentage of people treated with drug therapy do not reach their treatment goals. The findings in this study provide at least a partial explanation for why many patients receiving therapy do not reach their treatment goals: they require a larger reduction in LDL cholesterol than many therapies can provide. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
42. Assessment of Committed Effective Dose due to consumption of Red Sea coral reef fishes collected from the local market (Sudan)
- Author
-
Hassona, Rifaat K., Sam, A.K., Osman, O.I., Sirelkhatim, D.A., and LaRosa, J.
- Subjects
- *
CONTAMINATION of edible fish , *RADIOACTIVE contamination of food , *POLONIUM isotopes , *CESIUM isotopes , *INGESTION , *DOSE-response relationship (Radiation) - Abstract
An assessment of Committed Effective Dose (CED) due to consumption of Red Sea fish containing 210Po and 137Cs was performed for 23 different marine fish samples collected from the local market at Port Sudan. The fish were classified according to their feeding habits into three categories: carnivores, herbivores, and omnivores. Measured activity concentrations of 210Po were found in the ranges 0.25–6.42 (carnivores), 0.7–5 (omnivores) and 1.5–3.8 (herbivores) Bq/kg fresh weight. In the same study, activity concentrations of Cs-137 were determined to be in the ranges 0.1–0.46 (carnivores), 0.09–0.35 (omnivores) and 0.09–0.32 (herbivores) Bq/kg fresh weight, which were several times lower than those of 210Po. Appropriate conversion factors were used to derive the CED, which was found to be 0.012, 0.01 and 0.01 (µSv/yr) in carnivores, omnivores and herbivores, respectively, for 137Cs. This contributes about 0.4% of the total dose exclusively by ingestion of fish. For 210Po, it was found to be 3.47, 4.81 and 4.14 (µSv/yr) in carnivores, omnivores and herbivores, respectively, which represents 99.6% of the total dose (exclusively by ingestion of fish). The results of CED calculations suggest that the dose received by the Sudanese population from the consumption of marine fish is rather small and that the contribution of 137Cs is negligible compared to 210Po. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
43. Relative importance of food and water pathways in the bio-accumulation of $sup 65$Zn
- Author
-
LaRosa, J
- Published
- 1974
44. Final Measurement of the ^{235}U Antineutrino Energy Spectrum with the PROSPECT-I Detector at HFIR.
- Author
-
Andriamirado M, Balantekin AB, Bass CD, Bergeron DE, Bernard EP, Bowden NS, Bryan CD, Carr R, Classen T, Conant AJ, Deichert G, Delgado A, Diwan MV, Dolinski MJ, Erickson A, Foust BT, Gaison JK, Galindo-Uribari A, Gilbert CE, Gokhale S, Grant C, Hans S, Hansell AB, Heeger KM, Heffron B, Jaffe DE, Jayakumar S, Ji X, Jones DC, Koblanski J, Kunkle P, Kyzylova O, LaBelle D, Lane CE, Langford TJ, LaRosa J, Littlejohn BR, Lu X, Maricic J, Mendenhall MP, Meyer AM, Milincic R, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Nour S, Palomino Gallo JL, Pushin DA, Qian X, Roca C, Rosero R, Searles M, Surukuchi PT, Sutanto F, Tyra MA, Venegas-Vargas D, Weatherly PB, Wilhelmi J, Woolverton A, Yeh M, Zhang C, and Zhang X
- Abstract
This Letter reports one of the most precise measurements to date of the antineutrino spectrum from a purely ^{235}U-fueled reactor, made with the final dataset from the PROSPECT-I detector at the High Flux Isotope Reactor. By extracting information from previously unused detector segments, this analysis effectively doubles the statistics of the previous PROSPECT measurement. The reconstructed energy spectrum is unfolded into antineutrino energy and compared with both the Huber-Mueller model and a spectrum from a commercial reactor burning multiple fuel isotopes. A local excess over the model is observed in the 5-7 MeV energy region. Comparison of the PROSPECT results with those from commercial reactors provides new constraints on the origin of this excess, disfavoring at 2.0 and 3.7 standard deviations the hypotheses that antineutrinos from ^{235}U are solely responsible and noncontributors to the excess observed at commercial reactors, respectively.
- Published
- 2023
- Full Text
- View/download PDF
45. Joint Determination of Reactor Antineutrino Spectra from ^{235}U and ^{239}Pu Fission by Daya Bay and PROSPECT.
- Author
-
An FP, Andriamirado M, Balantekin AB, Band HR, Bass CD, Bergeron DE, Berish D, Bishai M, Blyth S, Bowden NS, Bryan CD, Cao GF, Cao J, Chang JF, Chang Y, Chen HS, Chen SM, Chen Y, Chen YX, Cheng J, Cheng ZK, Cherwinka JJ, Chu MC, Classen T, Conant AJ, Cummings JP, Dalager O, Deichert G, Delgado A, Deng FS, Ding YY, Diwan MV, Dohnal T, Dolinski MJ, Dolzhikov D, Dove J, Dvořák M, Dwyer DA, Erickson A, Foust BT, Gaison JK, Galindo-Uribarri A, Gallo JP, Gilbert CE, Gonchar M, Gong GH, Gong H, Grassi M, Gu WQ, Guo JY, Guo L, Guo XH, Guo YH, Guo Z, Hackenburg RW, Hans S, Hansell AB, He M, Heeger KM, Heffron B, Heng YK, Hor YK, Hsiung YB, Hu BZ, Hu JR, Hu T, Hu ZJ, Huang HX, Huang JH, Huang XT, Huang YB, Huber P, Koblanski J, Jaffe DE, Jayakumar S, Jen KL, Ji XL, Ji XP, Johnson RA, Jones DC, Kang L, Kettell SH, Kohn S, Kramer M, Kyzylova O, Lane CE, Langford TJ, LaRosa J, Lee J, Lee JHC, Lei RT, Leitner R, Leung JKC, Li F, Li HL, Li JJ, Li QJ, Li RH, Li S, Li SC, Li WD, Li XN, Li XQ, Li YF, Li ZB, Liang H, Lin CJ, Lin GL, Lin S, Ling JJ, Link JM, Littenberg L, Littlejohn BR, Liu JC, Liu JL, Liu JX, Lu C, Lu HQ, Lu X, Luk KB, Ma BZ, Ma XB, Ma XY, Ma YQ, Mandujano RC, Maricic J, Marshall C, McDonald KT, McKeown RD, Mendenhall MP, Meng Y, Meyer AM, Milincic R, Mueller PE, Mumm HP, Napolitano J, Naumov D, Naumova E, Neilson R, Nguyen TMT, Nikkel JA, Nour S, Ochoa-Ricoux JP, Olshevskiy A, Palomino JL, Pan HR, Park J, Patton S, Peng JC, Pun CSJ, Pushin DA, Qi FZ, Qi M, Qian X, Raper N, Ren J, Morales Reveco C, Rosero R, Roskovec B, Ruan XC, Searles M, Steiner H, Sun JL, Surukuchi PT, Tmej T, Treskov K, Tse WH, Tull CE, Tyra MA, Varner RL, Venegas-Vargas D, Viren B, Vorobel V, Wang CH, Wang J, Wang M, Wang NY, Wang RG, Wang W, Wang W, Wang X, Wang Y, Wang YF, Wang Z, Wang Z, Wang ZM, Weatherly PB, Wei HY, Wei LH, Wen LJ, Whisnant K, White C, Wilhelmi J, Wong HLH, Woolverton A, Worcester E, Wu DR, Wu FL, Wu Q, Wu WJ, Xia DM, Xie ZQ, Xing ZZ, Xu HK, Xu JL, Xu T, Xue T, Yang CG, Yang L, Yang YZ, Yao HF, Ye M, Yeh M, Young BL, Yu HZ, Yu ZY, Yue BB, Zavadskyi V, Zeng S, Zeng Y, Zhan L, Zhang C, Zhang FY, Zhang HH, Zhang JW, Zhang QM, Zhang SQ, Zhang X, Zhang XT, Zhang YM, Zhang YX, Zhang YY, Zhang ZJ, Zhang ZP, Zhang ZY, Zhao J, Zhao RZ, Zhou L, Zhuang HL, and Zou JH
- Abstract
A joint determination of the reactor antineutrino spectra resulting from the fission of ^{235}U and ^{239}Pu has been carried out by the Daya Bay and PROSPECT Collaborations. This Letter reports the level of consistency of ^{235}U spectrum measurements from the two experiments and presents new results from a joint analysis of both data sets. The measurements are found to be consistent. The combined analysis reduces the degeneracy between the dominant ^{235}U and ^{239}Pu isotopes and improves the uncertainty of the ^{235}U spectral shape to about 3%. The ^{235}U and ^{239}Pu antineutrino energy spectra are unfolded from the jointly deconvolved reactor spectra using the Wiener-SVD unfolding method, providing a data-based reference for other reactor antineutrino experiments and other applications. This is the first measurement of the ^{235}U and ^{239}Pu spectra based on the combination of experiments at low- and highly enriched uranium reactors.
- Published
- 2022
- Full Text
- View/download PDF
46. Joint Measurement of the ^{235}U Antineutrino Spectrum by PROSPECT and STEREO.
- Author
-
Almazán H, Andriamirado M, Balantekin AB, Band HR, Bass CD, Bergeron DE, Bernard L, Blanchet A, Bonhomme A, Bowden NS, Bryan CD, Buck C, Classen T, Conant AJ, Deichert G, Del Amo Sanchez P, Delgado A, Diwan MV, Dolinski MJ, El Atmani I, Erickson A, Foust BT, Gaison JK, Galindo-Uribarri A, Gilbert CE, Hans S, Hansell AB, Heeger KM, Heffron B, Jaffe DE, Jayakumar S, Ji X, Jones DC, Koblanski J, Kyzylova O, Labit L, Lamblin J, Lane CE, Langford TJ, LaRosa J, Letourneau A, Lhuillier D, Licciardi M, Lindner M, Littlejohn BR, Lu X, Maricic J, Materna T, Mendenhall MP, Meyer AM, Milincic R, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Nour S, Palomino JL, Pessard H, Pushin DA, Qian X, Réal JS, Ricol JS, Roca C, Rogly R, Rosero R, Salagnac T, Savu V, Schoppmann S, Searles M, Sergeyeva V, Soldner T, Stutz A, Surukuchi PT, Tyra MA, Varner RL, Venegas-Vargas D, Vialat M, Weatherly PB, White C, Wilhelmi J, Woolverton A, Yeh M, Zhang C, and Zhang X
- Abstract
The PROSPECT and STEREO collaborations present a combined measurement of the pure ^{235}U antineutrino spectrum, without site specific corrections or detector-dependent effects. The spectral measurements of the two highest precision experiments at research reactors are found to be compatible with χ^{2}/ndf=24.1/21, allowing a joint unfolding of the prompt energy measurements into antineutrino energy. This ν[over ¯]_{e} energy spectrum is provided to the community, and an excess of events relative to the Huber model is found in the 5-6 MeV region. When a Gaussian bump is fitted to the excess, the data-model χ^{2} value is improved, corresponding to a 2.4σ significance.
- Published
- 2022
- Full Text
- View/download PDF
47. Nonfuel Antineutrino Contributions in the High Flux Isotope Reactor.
- Author
-
Balantekin AB, Band HR, Bass CD, Bergeron DE, Berish D, Bowden NS, Brodsky JP, Bryan CD, Classen T, Conant AJ, Deichert G, Diwan MV, Dolinski MJ, Erickson A, Foust BT, Gaison JK, Galindo-Uribarri A, Gilbert CE, Hackett BT, Hans S, Hansell AB, Heeger KM, Heffron B, Jaffe DE, Ji X, Jones DC, Kyzylova O, Lane CE, Langford TJ, LaRosa J, Littlejohn BR, Lu X, Maricic J, Mendenhall MP, Milincic R, Mitchell I, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Norcini D, Nour S, Palomino-Gallo JL, Pushin DA, Qian X, Romero-Romero E, Rosero R, Surukuchi PT, Tyra MA, Varner RL, White C, Wilhelmi J, Woolverton A, Yeh M, Zhang A, Zhang C, and Zhang X
- Abstract
Reactor neutrino experiments have seen major improvements in precision in recent years. With the experimental uncertainties becoming lower than those from theory, carefully considering all sources of ν ¯ e is important when making theoretical predictions. One source of ν ¯ e that is often neglected arises from the irradiation of the nonfuel materials in reactors. The ν ¯ e rates and energies from these sources vary widely based on the reactor type, configuration, and sampling stage during the reactor cycle and have to be carefully considered for each experiment independently. In this article, we present a formalism for selecting the possible ν ¯ e sources arising from the neutron captures on reactor and target materials. We apply this formalism to the High Flux Isotope Reactor (HFIR) at Oak Ridge National Laboratory, the ν ¯ e source for the the Precision Reactor Oscillation and Spectrum Measurement (PROSPECT) experiment. Overall, we observe that the nonfuel ν ¯ e contributions from HFIR to PROSPECT amount to 1% above the inverse beta decay threshold with a maximum contribution of 9% in the 1.8-2.0 MeV range. Nonfuel contributions can be particularly high for research reactors like HFIR because of the choice of structural and reflector material in addition to the intentional irradiation of target material for isotope production. We show that typical commercial pressurized water reactors fueled with low-enriched uranium will have significantly smaller nonfuel ν ¯ e contribution.
- Published
- 2020
- Full Text
- View/download PDF
48. Measurement of the Antineutrino Spectrum from ^{235}U Fission at HFIR with PROSPECT.
- Author
-
Ashenfelter J, Balantekin AB, Band HR, Bass CD, Bergeron DE, Berish D, Bowden NS, Brodsky JP, Bryan CD, Cherwinka JJ, Classen T, Conant AJ, Cox AA, Davee D, Dean D, Deichert G, Diwan MV, Dolinski MJ, Erickson A, Febbraro M, Foust BT, Gaison JK, Galindo-Uribarri A, Gilbert CE, Gilje KE, Hackett BT, Hans S, Hansell AB, Heeger KM, Insler J, Jaffe DE, Ji X, Jones DC, Kyzylova O, Lane CE, Langford TJ, LaRosa J, Littlejohn BR, Lu X, Martinez Caicedo DA, Matta JT, McKeown RD, Mendenhall MP, Minock JM, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Norcini D, Nour S, Pushin DA, Qian X, Romero-Romero E, Rosero R, Sarenac D, Surukuchi PT, Telles AB, Tyra MA, Varner RL, Viren B, White C, Wilhelmi J, Wise T, Yeh M, Yen YR, Zhang A, Zhang C, and Zhang X
- Abstract
This Letter reports the first measurement of the ^{235}U ν[over ¯]_{e} energy spectrum by PROSPECT, the Precision Reactor Oscillation and Spectrum experiment, operating 7.9 m from the 85 MW_{th} highly enriched uranium (HEU) High Flux Isotope Reactor. With a surface-based, segmented detector, PROSPECT has observed 31678±304(stat) ν[over ¯]_{e}-induced inverse beta decays, the largest sample from HEU fission to date, 99% of which are attributed to ^{235}U. Despite broad agreement, comparison of the Huber ^{235}U model to the measured spectrum produces a χ^{2}/ndf=51.4/31, driven primarily by deviations in two localized energy regions. The measured ^{235}U spectrum shape is consistent with a deviation relative to prediction equal in size to that observed at low-enriched uranium power reactors in the ν[over ¯]_{e} energy region of 5-7 MeV.
- Published
- 2019
- Full Text
- View/download PDF
49. Preparation and calibration of a 231 Pa reference material.
- Author
-
Essex RM, Williams RW, Treinen KC, Collé R, Fitzgerald R, Galea R, Keightley J, LaRosa J, Laureano-Pérez L, Nour S, and Pibida L
- Abstract
A
231 Pa reference material has been characterized for amount of protactinium. This reference material is primarily intended for calibration of233 Pa tracers produced for235 U-231 Pa model age measurements associated with nuclear forensics and nuclear safeguards. Primary measurements for characterization were made by isotope dilution mass spectrometry of a purified231 Pa solution using a233 Pa isotopic spike. The spike was calibrated by allowing multiple aliquots of the233 Pa spike solution to decay to233 U and then measuring the ingrown233 U by isotope dilution mass spectrometry using a certified uranium assay and isotopic standard as a reverse-spike. The new231 Pa reference material will simplify calibration of the233 Pa isotope dilution spikes, provide metrological traceability, and potentially reduce the overall measurement uncertainty of model ages., Competing Interests: Compliance with ethical standards Conflict of interest All authors declare that they have no conflict of interest.- Published
- 2019
- Full Text
- View/download PDF
50. First Search for Short-Baseline Neutrino Oscillations at HFIR with PROSPECT.
- Author
-
Ashenfelter J, Balantekin AB, Baldenegro C, Band HR, Bass CD, Bergeron DE, Berish D, Bignell LJ, Bowden NS, Bricco J, Brodsky JP, Bryan CD, Bykadorova Telles A, Cherwinka JJ, Classen T, Commeford K, Conant AJ, Cox AA, Davee D, Dean D, Deichert G, Diwan MV, Dolinski MJ, Erickson A, Febbraro M, Foust BT, Gaison JK, Galindo-Uribarri A, Gilbert CE, Gilje KE, Glenn A, Goddard BW, Hackett BT, Han K, Hans S, Hansell AB, Heeger KM, Heffron B, Insler J, Jaffe DE, Ji X, Jones DC, Koehler K, Kyzylova O, Lane CE, Langford TJ, LaRosa J, Littlejohn BR, Lopez F, Lu X, Martinez Caicedo DA, Matta JT, McKeown RD, Mendenhall MP, Miller HJ, Minock JM, Mueller PE, Mumm HP, Napolitano J, Neilson R, Nikkel JA, Norcini D, Nour S, Pushin DA, Qian X, Romero-Romero E, Rosero R, Sarenac D, Seilhan BS, Sharma R, Surukuchi PT, Trinh C, Tyra MA, Varner RL, Viren B, Wagner JM, Wang W, White B, White C, Wilhelmi J, Wise T, Yao H, Yeh M, Yen YR, Zhang A, Zhang C, Zhang X, and Zhao M
- Abstract
This Letter reports the first scientific results from the observation of antineutrinos emitted by fission products of ^{235}U at the High Flux Isotope Reactor. PROSPECT, the Precision Reactor Oscillation and Spectrum Experiment, consists of a segmented 4 ton ^{6}Li-doped liquid scintillator detector covering a baseline range of 7-9 m from the reactor and operating under less than 1 m water equivalent overburden. Data collected during 33 live days of reactor operation at a nominal power of 85 MW yield a detection of 25 461±283 (stat) inverse beta decays. Observation of reactor antineutrinos can be achieved in PROSPECT at 5σ statistical significance within 2 h of on-surface reactor-on data taking. A reactor model independent analysis of the inverse beta decay prompt energy spectrum as a function of baseline constrains significant portions of the previously allowed sterile neutrino oscillation parameter space at 95% confidence level and disfavors the best fit of the reactor antineutrino anomaly at 2.2σ confidence level.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.